HIV

Human immunodeficiency virus

HIV (Human immunodeficiency virus) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically $CD4^+$ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of $CD4^+$ T cells through a number of mechanisms, including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected $CD4^+$ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When $CD4^+$ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.

(-)-Epigallocatechin Gallate

(EGCG; Epigallocatechol Gallate) Cat. No.: HY-13653

(-)-Epigallocatechin Gallate is a tea flavonoid with potent antioxidant, antiinflammatory, and anticarcinogenic properties. (-)-Epigallocatechin Gallate is reported to inhibit **EGFR** signaling and thereby exert anticancer effects.



Purity: 99.87%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

(2S,5S)-Censavudine

((2S,5S)-OBP-601; (2S,5S)-BMS-986001) Cat. No.: HY-16776A

(2S,5S)-Censavudine ((2S,5S)-OBP-601) is the (2S,5S)-enantiomer of Censavudine. Censavudine, a nucleoside reverse transcriptase inhibitor, is a potent HIV inhibitor.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(Rac)-Efavirenz-d4

Cat. No.: HY-10572BS

(Rac)-Efavirenz-d4 ((Rac)-DMP 266-d4) is a labelled racemic Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type **HIV-1 reverse transcriptase** with a K_i of 2.93 nM and exhibits an IC_{95} of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

(Rac)-Tenofovir-d6

Cat. No.: HY-113904S

(Rac)-Tenofovir-d6 ((Rac)-GS 1278-d6) is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a **nucleotide reverse transcriptase** inhibitor to treat **HIV** and chronic Hepatitis B (**HBV**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

(S)-Tenofovir

((S)-GS 1278; (S)-PMPA; (S)-TDF) Cat. No.: HY-W074930

(S)-Tenofovir ((S)-GS 1278) is the less active S-enantiomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(Z)-9-Propenyladenine

((Z)-Mutagenic Impurity of Tenofovir Disoproxil) Cat. No.: HY-100079A

(Z)-9-Propenyladenine is a mutagenic impurity in tenofovir disoproxil fumarate. Tenofovir is an antiretroviral drug known as nucleotide analogue reverse transcriptase (**NtART**) inhibitor, which blocks reverse transcriptase, a crucial virus enzyme in HIV-1 and HBV.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

(±)-BI-D

Cat. No.: HY-18601

(±)-BI-D is a potent ALLINI(An allosteric IN inhibitor) that binds integrase at the LEDGF/p75 binding site.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

1,3,5-Tricaffeoylquinic acid

Cat. No.: HY-N6926

1,3,5-Tricaffeoylquinic acid is a tricaffeoylquinic acid derivative isolated from H. populifolium with anti-HIV effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1-Deoxymannojirimycin hydrochloride

Cat. No.: HY-W009783

1-Deoxymannojirimycin hydrochloride is a selective **class I α1,2-mannosidase** inhibitor with an IC_{50} of 20 μM. 1-Deoxymannojirimycin hydrochloride is also a **N-linked glycosylation** inhibitor and inhibits **HIV1** strains. 1-Deoxymannojirimycin hydrochloride has antiviral activity.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

12-Oxocalanolide A

((±)-12-Oxocalanolide A) Cat. No.: HY-N1034

12-Oxocalanolide A (compound 6) is a potent inhibitor of reverse transcriptase from human immunodeficiency virus type 1 (HIV-1) with an IC_{50} and EC_{50} of 2.8 and 12 μM, respectively. 12-Oxocalanolide A is the analogue of Calanolide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2',3'-Dideoxyadenosine

Cat. No.: HY-W013441

2',3'-Dideoxyadenosine is an inhibitor of **HIV** replication. Antiretroviral activity. Antiviral efficacy.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

2-Hydroxyacetophenone

Cat. No.: HY-W002198

2-Hydroxyacetophenone is a principal root volatile of the Carissa edulis. 2-Hydroxyacetophenone shows inhibitory effects on infection of **HIV/SARS-CoV S pseudovirus** with an IC_{50} of 1.8 mM.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL,

2-Hydroxycinnamic acid

Cat. No.: HY-W012531

2-Hydroxycinnamic acid is isolated from the methanol extract of Cinnamomum cassia. 2-Hydroxycinnamic acid shows inhibitory effects on infection of **HIV/SARS-CoV S pseudovirus** with an IC_{50} of 0.3 mM.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

3'-Azido-3'-deoxy-5-methylcytidine

Cat. No.: HY-111640

3'-Azido-3'-deoxy-5-methylcytidine (CS-92) is a potent xenotropic murine leukemia-related retrovirus (**XMRV**) inhibitor with a CC_{50} of 43.5 μM in MCF-7 cells.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

3-Deazaadenosine

Cat. No.: HY-W013332

3-Deazaadenosine is an inhibitor of **S-adenosylhomocysteine hydrolase**, with a K_i of 3.9 μM; 3-Deazaadenosine has anti-inflammatory, anti-proliferative and anti-**HIV** activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3-Deazaadenosine hydrochloride

Cat. No.: HY-W013332A

3-Deazaadenosine (hydrochloride) is an inhibitor of **S-adenosylhomocysteine hydrolase**, with a K_i of 3.9 μM; 3-Deazaadenosine has anti-inflammatory, anti-proliferative and anti-**HIV** activity.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

4'-Ethynyl-2'-deoxyadenosine

Cat. No.: HY-125810

4'-Ethynyl-2'-deoxyadenosine (4'-E-dA), a nucleoside **reverse transcriptase (RT)** inhibitor, is an antiretroviral agent which is potent against drug-resistant HIV variants, with an EC_{50} of 98 nM in MT-4 cells for anti-HIV-1 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-(N,N-Hexamethylene)-amiloride

(Hexamethylene amiloride; HMA)

Cat. No.: HY-128067

5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent **Na^+/H^+ exchanger** inhibitor, which decreases the intracellular pH (pH_i) and induces apoptosis in leukemic cells.



Purity: 98.42%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

5-Fluorouracil

(5-FU)

Cat. No.: HY-90006

5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects **pyrimidine synthesis** by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces **apoptosis** and can be used as a chemical sensitizer.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 1 g, 5 g

5-Fluorouracil-15N2

Cat. No.: HY-90006S2

5-Fluorouracil-15N2 is the 15N-labeled 5-Fluorouracil. 5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects **pyrimidine synthesis** by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5-Fluorouracil-d1

(5-FU-d1) Cat. No.: HY-90006S

5-Fluorouracil-d1 (5-FU-d1) is the deuterium labeled 5-Fluorouracil. 5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects **pyrimidine synthesis** by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 50 mg

7-Deaza-2',3'-dideoxyguanosine

(7-Deaza-ddG) Cat. No.: HY-138592

7-Deaza-2',3'-dideoxyguanosine (7-Deaza-ddG) is a 2',3'-dideoxynucleoside 5'-triphosphate, which can inhibit **HIV-1 reverse transcriptase** with a K_i of 25 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

9-Aminoacridine

(Aminacrine) Cat. No.: HY-B1422

9-Aminoacridine (Aminacrine) is a highly fluorescent dye used as a topical antiseptic and experimentally as a mutagen, an intracellular pH indicator. 9-Aminoacridine is an effective antibacterial agent with caries-disclosing features.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

9-Propenyladenine (Mutagenic Impurity of Tenofovir Disoproxil; Tenofovir Impurity 2)

Cat. No.: HY-100079

9-Propenyladenine is a mutagenic impurity in tenofovir disoproxil fumarate. Tenofovir is an antiretroviral drug known as nucleotide analogue reverse transcriptase inhibitors, which block reverse transcriptase, a crucial virus enzyme in HIV-1 and HBV.



Purity: 96.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

A3N19

Cat. No.: HY-146031

A3N19 is a potent **HIV-1 non-nucleoside reverse transcriptase** inhibitor, with an EC_{50} of 3.28 nM against HIV-1 IIIB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abacavir

Cat. No.: HY-17423

Abacavir is a potent **nucleoside analog reverse-transcriptase inhibitor (NRTI)**.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Abacavir-d4

Cat. No.: HY-17423S

Abacavir-d4 is the deuterium labeled Abacavir. Abacavir is a potent **nucleoside analog reverse-transcriptase inhibitor (NRTI)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ABBV-744

Cat. No.: HY-112090

ABBV-744 is a first-in-class, orally active and selective inhibitor of the **BDII domain** of BET family proteins with IC_{50} values ranging from 4 to 18 nM for BRD2, BRD3, BRD4 and BRDT.



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Acetyl-pepstatin

Cat. No.: HY-P1436

Acetyl-pepstatin is a potent classical inhibitor of aspartic proteases (**PRs**) with XMRV PR and HIV-1 PR K_i values of 712 nM and 13 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aeroplysinin 1

((+)-Aeroplysinin-1) Cat. No.: HY-19827

Aeroplysinin 1 ((+)-Aeroplysinin-1), a secondary metabolite isolated from marine sponges, shows potent antibiotic effects on Gram-positive **bacteria** and exerts antiviral activity against **HIV-1** (IC_{50}=14.6 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 100 μg

AIC-292

Cat. No.: HY-19925

AIC-292 is a potent and selective inhibitor of HIV-1 nonnucleoside reverse transcriptase. AIC-292 inhibits wild-type HIV-1 laboratory strains at low nanomolar concentrations. AIC-292 displays potent antiviral in vivo efficacy in a mouse xenograft model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AL-470

Cat. No.: HY-146009

AL-470 is a potent antiviral agent with **EC_{50}** values of 0.27, 0.63, and 0.35 μM against **HIV-1**, **HIV-2**, and **EV-A71**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aloperine

Cat. No.: HY-13516

Aloperine is an alkaloid in sophora plants such as Sophora alopecuroides L, which has shown anti-cancer, anti-inflammatory and anti-virus properties. Aloperine is widely used to treat patients with allergic contact dermatitis eczema and other skin inflammation in China.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

AMD 3465

(GENZ-644494)

Cat. No.: HY-15971A

AMD 3465 (GENZ-644494) is a potent antagonist of **CXCR4**, inhibits binding of 12G5 mAb and $CXCL12^{AF647}$ to **CXCR4**, with **IC_{50}**s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of **X4 HIV** strains (**IC_{50}**: 1-10 nM), but has no effect on CCR5-using...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMD 3465 hexahydrobromide

(GENZ-644494 hexahydrobromide)

Cat. No.: HY-15971

AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide) is a potent antagonist of **CXCR4**, inhibits binding of 12G5 mAb and $CXCL12^{AF647}$ to **CXCR4**, with **IC_{50}**s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of **X4 HIV** strains...



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amphotericin B methyl ester

Cat. No.: HY-135327

Amphotericin B methyl ester is the methyl ester derivative of the polyene antibiotic Amphotericin B (A634250). Amphotericin B methyl ester is the cholesterol-binding compound possesses significant antifungal activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

Amphotericin B methyl ester hydrochloride

Cat. No.: HY-135327A

Amphotericin B methyl ester hydrochloride is the methyl ester derivative of the polyene antibiotic Amphotericin B (A634250). Amphotericin B methyl ester hydrochloride is the cholesterol-binding compound possesses significant antifungal activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Amprenavir

(VX-478)

Cat. No.: HY-17430

Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.09 μM.



Purity: 99.58%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 25 mg, 50 mg

Amprenavir-d4

Cat. No.: HY-17430S

Amprenavir-d4 is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.09 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Amprenavir-d4-1

(VX-478-d4-1)

Cat. No.: HY-17430S1

Amprenavir-d4-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

Amustaline dihydrochloride

(S-303 dihydrochloride) Cat. No.: HY-106991A

Amustaline (S-303) dihydrochloride, a nucleic acid-targeted alkylator, is an efficient pathogen inactivation agent for blood components containing red blood cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Amylmetacresol

Cat. No.: HY-121527

Amylmetacresol possesses antiviral (such HIV) effect. Amylmetacresol has the potential for the study in sore throat.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 500 mg, 1 g

Antiviral agent 9

Cat. No.: HY-139845

Antiviral agent 9 reaches a single-digit picomolar EC_{50} value (0.006 nM) against **HIV-1** and nearly 300-fold higher selectivity index (SI) compared to tenofovir alafenamide fumarate (TAF).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apabetalone

(RVX-208; RVX000222) Cat. No.: HY-16652

Apabetalone (RVX-208) is an inhibitor of **BET** transcriptional regulators with selectivity for the second bromodomain. The IC_{50}s are 87 μM and 0.51 μM for **BD1** and **BD2**, respectively.



Purity: 99.47%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Apelin-17(human, bovine)

Cat. No.: HY-P1066

Apelin-17(human, bovine) is an endogenous orphan G protein-coupled receptor **APJ** agonist.
Apelin-17(human, bovine) binds to human APJ receptors expressed in HEK 293 cells (pIC_{50}=9.02).

KFRRQRPRLSHKGPMPF

Purity: 98.86%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-17(human, bovine) TFA

Cat. No.: HY-P1066A

Apelin-17(human, bovine) TFA is an endogenous orphan G protein-coupled receptor **APJ** agonist.
Apelin-17(human, bovine) TFA binds to human APJ receptors expressed in HEK 293 cells (pIC_{50}=9.02).

KFRRQRPRLSHKGPMPF (TFA salt)

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-36(human)

Cat. No.: HY-P1064

Apelin-36(human) is an endogenous orphan G protein-coupled receptor **APJ** agonist, with an EC_{50} of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC_{50}=8.61).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-36(human) TFA

Cat. No.: HY-P1064A

Apelin-36(human) TFA is an endogenous orphan G protein-coupled receptor **APJ** agonist, with an EC_{50} of 20 nM. Apelin-36(human) TFA shows high affinity to human APJ receptors expressed in HEK 293 cells ($pIC5_{50}$=8.61).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-36(rat, mouse)

Cat. No.: HY-P1065

Apelin-36(rat, mouse) is an endogenous orphan G protein-coupled receptor **APJ** agonist.
Apelin-36(rat, mouse) binds to APJ receptors with an IC_{50} of 5.4 nM, and potently inhibits cAMP production with an EC_{50} of 0.52 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apelin-36(rat, mouse) TFA

Cat. No.: HY-P1065A

Apelin-36(rat, mouse) TFA is an endogenous orphan G protein-coupled receptor **APJ** agonist.
Apelin-36(rat, mouse) TFA binds to APJ receptors with an IC_{50} of 5.4 nM, and potently inhibits cAMP production with an EC_{50} of 0.52 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aplaviroc
(AK 602; GSK 873140; GW 873140) Cat. No.: HY-17450

Aplaviroc (AK 602), a SDP derivative, is a **CCR5** antagonist, with **IC_{50}s** of 0.1-0.4 nM for HIV-1_{Ba-L}, HIV-1_{JRFL} and HIV-1_{MOKW}.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Aplaviroc hydrochloride (AK602 hydrochloride; GSK-873140 hydrochloride; GW-873140 hydrochloride) Cat. No.: HY-17450A

Aplaviroc (AK 602) hydrochloride, a SDP derivative, is a **CCR5** antagonist, with **IC_{50}s** of 0.1-0.4 nM for HIV-1_{Ba-L}, HIV-1_{JRFL} and HIV-1_{MOKW}.



Purity: 99.76%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 25 mg

Aprepitant
(MK-0869; MK-869; L-754030) Cat. No.: HY-10052

Aprepitant (MK-0869) is a selective and high-affinity **neurokinin 1 receptor** antagonist with a **K_d** of 86 pM.



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Apricitabine
(SPD754; AVX754) Cat. No.: HY-14913

Apricitabine (SPD754; AVX754), the (-) enantiomer of 2'-deoxy-3'-oxa-4'-thiocytidine (dOTC), is a highly selective and orally active **HIV-1 reverse transcriptase (RT)** inhibitor (**K_i**=0.08 μM), as well as inhibits DNA polymerases α, β, and γ with **K_i** value of 300 μM, 12 μM, and 112.25...



Purity: >98%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Atazanavir
(BMS-232632) Cat. No.: HY-17367

Atazanavir (BMS-232632), a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir (BMS-232632) is a substrate and inhibitor of **CYP3A4**, and an inhibitor and inducer of **P-glycoprotein (P-gp)**.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Atazanavir sulfate
(BMS-232632 sulfate) Cat. No.: HY-17367A

Atazanavir (BMS-232632) sulfate, a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration. Atazanavir sulfate is a substrate and inhibitor of **CYP3A4**, and an inhibitor and inducer of **P-glycoprotein (P-gp)**.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Atazanavir-d5
Cat. No.: HY-17367S3

Atazanavir-d5 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Atazanavir-d6
(BMS-232632-d6) Cat. No.: HY-17367S4

Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atazanavir-d9
(BMS-232632-d9) Cat. No.: HY-17367S2

Atazanavir-d9 (BMS-232632-d9) is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective **HIV-1 protease** inhibitor, is the first protease inhibitor approved for once-daily administration.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AzddMeC
(CS-92) Cat. No.: HY-105268

AzddMeC (CS-92) is an antiviral **nucleoside analogue** and a potent potent, selective and orally active **HIV-1 reverse transcriptase** and **HIV-1 replication** inhibitor. In **HIV-1**-infected human PBM cells and **HIV-1**-infected human macrophages, the **EC_{50}** values of AzddMeC are 9 nM and 6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZT triphosphate

(3'-Azido-3'-deoxythymidine-5'-triphosphate) Cat. No.: HY-116364

AZT triphosphate (3'-Azido-3'-deoxythymidine-5'-triphosphate) is a active triphosphate metabolite of Zidovudine (AZT). AZT triphosphate exhibits antiretroviral activity and inhibits replication of **HIV**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

AZT triphosphate TEA

(3'-Azido-3'-deoxythymidine-5'-triphosphate TEA) Cat. No.: HY-116364A

AZT triphosphate TFA (3'-Azido-3'-deoxythymidine-5'-triphosphate TFA) is a active triphosphate metabolite of Zidovudine (AZT). AZT triphosphate TFA exhibits antiretroviral activity and inhibits replication of **HIV**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Azt-pmap

Cat. No.: HY-120832

Azt-pmap, a nucleoside analogue, is an aryl phosphate derivative of AZT. Azt-pmap shows anti-HIV activity. AZT is a nucleoside reverse transcriptase inhibitor (NRTI) for HIV infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azulene

(Cyclopentacycloheptene) Cat. No.: HY-B0055

Azulene (Cyclopentacycloheptene) is as an isomer of naphthalene with high **anti-HIV** activity. Azulene, isolated from the distillation of chamomile oil, is a scaffold in medicinal chemistry.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 100 mg

Azvudine

(RO-0622; FNC) Cat. No.: HY-19314

Azvudine (RO-0622) is a potent **nucleoside reverse transcriptase** inhibitor (NRTI), with antiviral activity on **HIV**, **HBV** and **HCV**. Azvudine exerts highly potent inhibition on HIV-1 (EC_{50}s ranging from 0.03 to 6.92 nM) and HIV-2 (EC_{50}s ranging from 0.018 to 0.025 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azvudine hydrochloride

(RO-0622 hydrochloride; FNC hydrochloride) Cat. No.: HY-19314A

Azvudine (RO-0622) hydrochloride is a potent **nucleoside reverse transcriptase** inhibitor (NRTI), with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Baicalin

(Baicalein 7-O-β-D-glucuronide) Cat. No.: HY-N0197

Baicalin, as a flavonoid glycoside, is an allosteric carnitine palmityl transferase 1 (**CPT1**) activator. Baicalin reduces the expression of **NF-κB**.



Purity: 99.17%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Bellidifolin

Cat. No.: HY-N2000

Bellidifolin is a xanthone isolated from the stems of Swertia punicea, with hepatoprotective, hypoglycemic, anti-oxidation, anti-inflammatory and antitumor activities. Bellidifolin also acts as a **viral protein R (Vpr)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

beta-L-D4A

(2'3'-didehydro-2'3'-dideoxyadenosine) Cat. No.: HY-100260

beta-L-D4A is a nucleoside **HIV-1 reverse transcriptase** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Betulin diacetate

(Betulin 3,28-diacetate) Cat. No.: HY-N9437

Betulin diacetate, a triterpene and derivative of Betulin, is an anti-AID agent and also possesses anti-cancer activity.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

Betulinic acid

(Lupatic acid; Betulic acid) Cat. No.: HY-10529

Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic **topoisomerase I** inhibitor, with an IC_{50} of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Bevirimat

(PA-457; MPC-4326; YK FH312) Cat. No.: HY-N0842

Bevirimat (PA-457; MPC-4326; YK FH312) is an anti-HIV drug derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition.



Purity: 98.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

BI 224436

Cat. No.: HY-18595

BI 224436 is a novel **HIV-1** noncatalytic site integrase inhibitor with EC_{50} values of less than 15 nM against different HIV-1 laboratory strains.



Purity: 99.74%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Bictegravir

(GS-9883) Cat. No.: HY-17605

Bictegravir (GS-9883) is a potent inhibitor of **HIV-1 integrase** with an IC_{50} of 7.5 nM.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Birinapant

(TL32711) Cat. No.: HY-16591

Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for **XIAP** and **cIAP1** with K_ds of 45 nM and less than 1 nM, respectively.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-378806

(BMS-806) Cat. No.: HY-14134

BMS-378806 is a potent **HIV-1** attachment inhibitor that interferes with CD4-gp120 interactions. BMS-378806 selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC_{50} of 0.85-26.5 nM in virus.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-707035

Cat. No.: HY-13269

BMS-707035 is an HIV-1 integrase (IN) inhibitor with an IC50 value of 15 nM.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS-986224

Cat. No.: HY-139485

BMS-986224 is a potent, selective and orally bioavailable **APJ receptor** agonist (K_d = 0.3 nM). BMS-986224 exhibits similar receptor binding and signaling profile to (Pyr[1]) apelin-13. BMS-986224 has the potential for the research of heart failure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BNM-III-170

Cat. No.: HY-115488A

BNM-III-170 is able to inhibit **HIV-1** viral entry into target cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD-6929

Cat. No.: HY-100719

BRD-6929 is a potent, selective brain-penetrant inhibitor of class I histone deacetylase **HDAC1** and **HDAC2** inhibitor with IC_{50} of 1 nM and 8 nM, respectively.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

BRD-K98645985

Cat. No.: HY-114268

BRD-K98645985 is a **BAF (mammalian SWI/SNF) transcriptional repression** inhibitor with an EC_{50} of ~2.37 μM. BRD-K98645985 binds ARID1A-specific **BAF** complexes, prevents nucleosomal positioning, and potently reverses **HIV-1** latency, without T cell activation or toxicity.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BRD3308

Cat. No.: HY-19618

BRD3308 is a highly selective **HDAC3** inhibitor with an IC_{50} of 54 nM. BRD3308 is 23-fold selectivity for **HDAC3** over HDAC1 (IC_{50} of 1.26 μM) or HDAC2 (IC_{50} of 1.34 μM).



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Bromhexine hydrochloride

Cat. No.: HY-B0372A

Bromhexine hydrochloride is a potent and specific **TMPRSS2** protease inhibitor with an IC_{50} of 0.75 μM. Bromhexine hydrochloride can prevent and manage **SARS-CoV-2** infection. Bromhexine hydrochloride is an **autophagy** agonist.



Purity: 99.39%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Bromhexine-d3 hydrochloride

Cat. No.: HY-B0372AS

Bromhexine-d3 (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bryostatin 1

Cat. No.: HY-105231

Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable **PKC** modulator.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 μg

Bz-RS-iSer(3-Ph)-OMe

Cat. No.: HY-W009245

Bz-RS-iSer(3-Ph)-OMe (compound 2), a Taxol derivative, inhibits HSV replication cycle at low cytotoxicity, blocks mitotic divisions of Vero cells, influences M-MSV induced tumor size and affects immune response by inhibiting PHA-induced T lymphocyte proliferation.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

CA inhibitor 1

(GS-6207 analog)

Cat. No.: HY-124594

CA inhibitor 1 (GS-6207 analog) is a potent **HIV** capsid inhibitor for HIV inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Cabotegravir

(GSK-1265744; S/GSK1265744)

Cat. No.: HY-15592

Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μM) and OAT3 (IC50 0.41 μM).



Purity: 98.04%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Cabotegravir-d3

(GSK-1265744-d3; S/GSK1265744-d3)

Cat. No.: HY-15592S

Cabotegravir-d3 (GSK-1265744-d3) is the deuterium labeled Cabotegravir. Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cabotegravir-d5

(GSK-1265744-d5; S/GSK1265744-d5)

Cat. No.: HY-15592S1

Cabotegravir-d5 is deuterium labeled Cabotegravir.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Carbenoxolone-d4

Cat. No.: HY-B1588S

Carbenoxolone-d4 is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties.



Purity: >98%
Clinical Data:
Size: 1 mg, 5 mg

CCR5 antagonist 1

Cat. No.: HY-100261

CCR5 antagonist 1 is a **CCR5** antagonist which can inhibit **HIV** replication extracted from WO 2004054974 A2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK9-IN-1

Cat. No.: HY-13231

CDK9-IN-1 is a novel, selective **CDK9** inhibitor for the treatment of HIV infection, with an IC_{50} of 39 nM for CDK9/CycT1, extracted from reference, compound 87.



Purity: 98.52
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Celgosivir

(MBI 3253; MDL 28574; MX3253)

Cat. No.: HY-16134

Celgosivir (MBI 3253; MDL 28574; MX3253) is an **α-glucosidase I** inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC_{50} of 1.27 μM in in vitro assay.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg

Celgosivir hydrochloride (MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride)

Cat. No.: HY-16134A

Celgosivir hydrochloride (MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride) is an **α-glucosidase I** inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC_{50} of 1.27 μM in in vitro assay.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Cenicriviroc

(TAK-652; TBR-652)

Cat. No.: HY-14882

Cenicriviroc (TAK-652) is an orally active, dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.



Purity: 98.07%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cenicriviroc Mesylate

(TAK-652 Mesylate; TBR-652 Mesylate)

Cat. No.: HY-14882A

Cenicriviroc Mesylate (TAK-652 Mesylate) is a dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.



Purity: 98.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Censavudine

(OBP-601; BMS-986001)

Cat. No.: HY-16776

Censavudine (OBP-601; BMS-986001), a **nucleoside analog**, is a **nucleoside reverse transcriptase** inhibitor. Censavudine is a potent **HIV** inhibitor with EC_{50} ranges from 30 nM to 81 nM and 450 nM to 890 nM for **HIV-2** and **HIV-1**, respectively.



Purity: 98.12%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Chloroquine

Cat. No.: HY-17589A

Chloroquine is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Chloroquine dihydrochloride

Cat. No.: HY-17589B

Chloroquine dihydrochloride is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Chloroquine phosphate

Cat. No.: HY-17589

Chloroquine phosphate is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg

Chloroquine-d4 phosphate

Cat. No.: HY-17589S1

Chloroquine-d4 phosphate is the deuterium labeled Chloroquine phosphate. Chloroquine phosphate is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chloroquine-d5

Cat. No.: HY-17589AS

Chloroquine D5 is deuterium labeled Chloroquine. Chloroquine is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an **autophagy** and **toll-like receptors (TLRs)** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chloroquine-d5 diphosphate

Cat. No.: HY-17589S

Chloroquine-d5 diphosphate is the deuterium labeled Chloroquine (phosphate). Chloroquine phosphate is an **antimalarial** and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CK-666

Cat. No.: HY-16926

CK-666 is a cell-permeable actin-related protein **Arp2/3 complex** inhibitor (IC_{50}=12 μM). CK-666 binds to Arp2/3 complex, stabilizes the inactive state of the complex, blocking movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) conformation.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Claficapavir

(A1752)

Cat. No.: HY-145560

Claficapavir (A1752) is a specific **nucleocapsid protein** (NC) inhibitor with an IC_{50} around 1 μM. Claficapavir strongly binds the HIV-1 NC (K_d=20 nM) thereby inhibiting the chaperone properties of NC and leading to good antiviral activity against the HIV-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Clathrin-IN-1

Cat. No.: HY-102068

Clathrin-IN-1 is a selective **clathrin-mediated endocytosis (CME)** inhibitor. Clathrin-IN-1 selectively inhibits amphiphysin association of clathrin terminal domain (TD) with an IC_{50} value of 12 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cobicistat

(GS-9350)

Cat. No.: HY-10493

Cobicistat is a potent and selective inhibitor of **cytochrome P450 3A (CYP3A) enzymes** with IC_{50}s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Corydine

Cat. No.: HY-N2571

Corydine is a naturally occurring alkaloid which can be extracted from plants such as Croton echinocarpus leaves. Corydine is efficient on inhibiting **reverse transcriptase** (RT) activity with an IC_{50} of 356.8 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CXCR4 antagonist 1

Cat. No.: HY-136437

CXCR4 antagonist 1 is a potent **CXCR4** antagonist. CXCR4 antagonist 1 has anti-**HIV** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CXCR4 antagonist 4

Cat. No.: HY-144285

CXCR4 antagonist 4 is a potent, orally active **CXCR4** antagonist (IC_{50}=24 nM) with diminished CYP 2D6 activity, improved PAMPA permeability, potent inhibition of human immunodeficiency virus entry (IC_{50}=7 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclotriazadisulfonamide

(CADA)

Cat. No.: HY-134809

Cyclotriazadisulfonamide (CADA) is a specific **CD4**-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cys-TAT(47-57)

(Cys-[HIV-Tat (47-57)])

Cat. No.: HY-P1801

Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine rich cell penetrating peptide derived from the HIV-1 transactivating protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

D77

Cat. No.: HY-18666

D77 is anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. D77 inhibits HIV-1(IIIB) replication by EC50 value of 23.8 μg/ml in MT-4 cell (5.03 μg/ml for C8166 cells).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dapivirine

(TMC120; R147681)

Cat. No.: HY-14266

Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and **nonnucleoside reverse transcriptase inhibitor (NRTI)**. Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dapivirine-d11

(TMC120-d11; R147681-d11)

Cat. No.: HY-14266S

Dapivirine-d11 (TMC120-d11) is the deuterium labeled Dapivirine. Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and **nonnucleoside reverse transcriptase inhibitor (NRTI)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

DAPTA

(D-Ala-peptide T-amide; Adaptavir)

Cat. No.: HY-P1034

DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively **CCR5**, and shows potent anti-HIV activities.



Purity: 95.16%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg

Darunavir

(TMC114; UIC-94017)

Cat. No.: HY-17040

Darunavir (TMC114), an orally active next generation **HIV protease** inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Darunavir Ethanolate

(TMC114 Ethanolate)

Cat. No.: HY-17041

Darunavir ethanolate (TMC114 Ethanolate) is a potent **HIV** protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a K_i of 1 nM for wild type HIV-1 protease.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Darunavir-d9

(TMC114-d9; UIC-94017-d9)

Cat. No.: HY-112585

Darunavir-d9 (TMC114-d9) is the deuterium labeled Darunavir. Darunavir (TMC114), an orally active next generation **HIV protease** inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

DDX3-IN-1

Cat. No.: HY-121832

DDX3-IN-1 (Compound 16f) is a DEAD-box polypeptide 3 (**DDX3**) inhibitor with **CC_{50}**s of 50 and 36 μM for **HIV** and **HCV**, respectively. Antiviral activity.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DDX3-IN-2

Cat. No.: HY-121969

DDX3-IN-2 is an active DEADbox polypeptide 3 (**DDX3**) inhibitor with an **IC_{50}** value of 0.3 μM. DDX3-IN-2 shows a broad spectrum of antiviral activity. DDX3-IN-2 has the potential to overcome **HIV** resistance.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Decanoyl-RVKR-CMK

(DecRVKRcmk)

Cat. No.: HY-107760

Decanoyl-RVKR-CMK (DecRVKRcmk) inhibits over-expressed gp160 processing and HIV-1 replication.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Decanoyl-RVKR-CMK TFA

(DecRVKRcmk TFA)

Cat. No.: HY-107760A

Decanoyl-RVKR-CMK (DecRVKRcmk) TFA inhibits over-expressed gp160 processing and HIV-1 replication.



Purity: 96.40%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Delavirdine

(U 90152; BHAP-U 90152)

Cat. No.: HY-10571

Delavirdine (U 90152) is a potent, highly specific and orally active **non-nucleoside reverse transcriptase** inhibitor (NNRTI).



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Delavirdine mesylate

(U 90152 mesylate; BHAP-U 90152 mesylate)

Cat. No.: HY-10571A

Delavirdine (U 90152) mesylate is a potent, highly specific and orally active **non-nucleoside reverse transcriptase** inhibitor (NNRTI).



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Dexelvucitabine

(Reverset; d-d4FC)

Cat. No.: HY-14920

Dexelvucitabine (Reverset; d-d4FC), a Cytidine (HY-B0158) analog, is an orally active **nucleoside reverse transcriptase** inhibitor. Dexelvucitabine is a powerful drug against **HIV-1-resistant viruses** containing a thymidine analog and/or M184V mutation in the viral polymerase.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dextran sulfate sodium salt (MW 16000-24000)

Cat. No.: HY-116282B

Dextran sulfate sodium salt (MW 16000-24000) is a is a polymer of anhydroglucose with the molecular weight range of 16000-24000. Dextran sulfate sodium salt inhibits the replication of the human immunodeficiency virus by preventing the adsorption of the virus into host cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Dextran sulfate sodium salt (MW 35000-45000)

Cat. No.: HY-116282C

Dextran sulfate sodium salt (MW 35000-45000) is a is a polymer of anhydroglucose with the molecular weight range of 35000-45000. Dextran sulfate sodium salt inhibits the replication of the human immunodeficiency virus by preventing the adsorption of the virus into host cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Dextran sulfate sodium salt (MW 4500-5500)

Cat. No.: HY-116282A

Dextran sulfate sodium salt (MW 4500-5500) is a is a polymer of anhydroglucose with the molecular weight range of 4500-5500. Dextran sulfate sodium salt inhibits the replication of the human immunodeficiency virus by preventing the adsorption of the virus into host cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg

Dextran sulfate sodium salt (MW 450000-550000)

Cat. No.: HY-116282D

Dextran sulfate sodium salt (MW 450000-550000) is a is a polymer of anhydroglucose with the molecular weight range of 450000-550000. Dextran sulfate sodium salt inhibits the replication of the human immunodeficiency virus by preventing the adsorption of the virus into host cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg

Didanosine

(2',3'-Dideoxyinosine; ddI)

Cat. No.: HY-B0249

Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM. Target: NRTIs; HIV Didanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Didanosine-d2

Cat. No.: HY-B0249S

Didanosine-d2 is the deuterium labeled Didanosine. Didanosine (Videx) is a reverse transcriptase inhibitor with an IC_{50} of 0.49 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dimercaprol

(2,3-Dimercapto-1-propanol; Dithioglycerol)

Cat. No.: HY-B1285

Dimercaprol (2,3-Dimercapto-1-propanol) is an anti-heavy metal-poisoning drug, which exhibits anti-**HIV** activity.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Dimethyl fumarate

Cat. No.: HY-17363

Dimethyl fumarate (DMF) is an orally active and brain-penetrant **Nrf2** activator and induces upregulation of antioxidant gene expression.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g

Diphyllin

Cat. No.: HY-N2532

Diphyllin is an arylnaphthalene lignan isolated from Justicia procumbens and is a potent **HIV-1** inhibitor with an IC50 of 0.38 μM. Diphyllin is active against **vesicular stomatitis virus (VSV)** and **influenza virus**.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Ditiocarb sodium

(Sodium diethyldithiocarbamate)

Cat. No.: HY-B1637

Ditiocarb sodium (Sodium diethyldithiocarbamate) is an accelerator of the rate of copper cementation. Sodium diethyldithiocarbamate reduces the incidence of **HIV** infection.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Dolutegravir

(S/GSK1349572)

Cat. No.: HY-13238

Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable **HIV integrase strand transfer** inhibitor with an IC_{50} of 2.7 nM for HIV-1 integrase-catalyzed strand transfer.



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dolutegravir intermediate-1

Cat. No.: HY-100083

Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Dolutegravir sodium

(S/GSK1349572 sodium)

Cat. No.: HY-13238A

Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable **HIV integrase strand transfer** inhibitor with an IC_{50} of 2.7 nM for HIV-1 integrase-catalyzed strand transfer.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Dolutegravir-d3

(S/GSK1349572-d3) Cat. No.: HY-13238S1

Dolutegravir-d3 (S/GSK1349572-d3) is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable **HIV integrase strand transfer** inhibitor with an IC_{50} of 2.7 nM for HIV-1 integrase-catalyzed strand transfer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dolutegravir-d5

(S/GSK1349572-d5) Cat. No.: HY-13238S2

Dolutegravir-d5 is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dolutegravir-d6 sodium

(S/GSK1349572-d6 sodium) Cat. No.: HY-13238AS

Dolutegravir-d6 sodium (S/GSK1349572-d6 sodium) is the deuterium labeled Dolutegravir sodium.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Doravirine

(MK-1439) Cat. No.: HY-16767

Doravirine (MK-1439) is a highly specific **HIV-1 nonnucleoside reverse transcriptase** inhibitor with IC_{50}s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and **K103N** and **Y181C reverse transcriptase** mutants, respectively.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Doxorubicin

(Hydroxydaunorubicin) Cat. No.: HY-15142A

Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits **topoisomerase II** with an IC_{50} of 2.67 μM, thus stopping DNA replication.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Doxorubicin hydrochloride

(Hydroxydaunorubicin hydrochloride) Cat. No.: HY-15142

Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human **DNA topoisomerase I** and **topoisomerase II** inhibitor with IC_{50}s of 0.8 μM and 2.67 μM, respectively.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

DPC-681

(DPH-153893) Cat. No.: HY-19400

DPC-681 is a potent and selective inhibitor of HIV protease with IC90s for wild-type HIV-1 of 4 to 40 nM. IC50 value: 4 - 40 nM Target: HIV protease in vitro: DPC 681 is extremely potent inhibitor of wild-type HIV-1.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Ebselen

(SPI-1005; PZ-51; CCG-39161) Cat. No.: HY-13750

Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent **voltage-dependent calcium channel (VDCC)** blocker. Ebselen potently inhibits M^{pro} (IC_{50}=0.67 μM) and **COVID-19** virus (EC_{50}=4.67 μM).Ebselen is an inhibitor of **HIV-1** capsid CTD dimerization.



Purity: 99.58%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Efavirenz

(DMP 266; EFV; L-743726) Cat. No.: HY-10572

Efavirenz (DMP 266) is a potent inhibitor of the wild-type **HIV-1 reverse transcriptase** with a K_i of 2.93 nM and exhibits an IC_{95} of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Efavirenz-d5

Cat. No.: HY-10572S

Efavirenz-d5 (DMP 266-d5) is the deuterium labeled Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type **HIV-1 reverse transcriptase** with a K_i of 2.93 nM and exhibits an IC_{95} of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.



Purity: >98%
Clinical Data:
Size: 500 μg, 5 mg

EFdA-TP

Cat. No.: HY-138561

EFdA-TP is a potent **nucleoside reverse transcriptase (RT)** inhibitor. EFdA-TP inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP inhibits **HIV-1** RT with multiple mechanisms.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EFdA-TP tetraammonium

Cat. No.: HY-138561A

EFdA-TP tetraammonium is a potent **nucleoside reverse transcriptase (RT)** inhibitor. EFdA-TP tetraammonium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetraammonium inhibits **HIV-1** RT with multiple mechanisms.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EFdA-TP tetrasodium

Cat. No.: HY-138561B

EFdA-TP tetrasodium is a potent **nucleoside reverse transcriptase (RT)** inhibitor. EFdA-TP tetrasodium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetrasodium inhibits **HIV-1** RT with multiple mechanisms.



Purity: 95.18%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Elsulfavirine

Cat. No.: HY-109056

Elsulfavirine is a reverse transcriptase inhibitors for **HIV-1** infection and is a new anti-HIV drug.



Purity: 99.63%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Elvitegravir

(GS-9137; JTK-303; D06677)

Cat. No.: HY-14740

Elvitegravir (GS-9137; JTK-303; D06677) is an **HIV integrase** inhibitor for HIV-1_{IIIB}, HIV-2_{EHO} and HIV-2_{ROD} with IC_{50} of 0.7 nM, 2.8 nM and 1.4 nM, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Elvitegravir-d8

(GS-9137-d8; JTK-303-d8; D06677-d8)

Cat. No.: HY-14740S

Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emivirine

(MKC-442)

Cat. No.: HY-15353

Emivirine (MKC-442) is a **non-nucleoside reverse transcriptase** inhibitors (NNRTIs) with K_i values of 0.20 and 0.01 μM for dTTP- and dGTP-dependent DNA or RNA polymerase activity, respectively. Emivirine displays potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Emtricitabine

(BW1592)

Cat. No.: HY-17427

Emtricitabine is a nucleoside reverse transcriptase inhibitor (**NRTI**) with an EC_{50} of 0.01 μM in PBMC cell. It is an antiviral drug for the treatment of **HIV** infection.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Emtricitabine S-oxide

(Emtricitabine sulfoxide; Emtricitabine Degradant-III)

Cat. No.: HY-100096

Emtricitabine S-oxide (Emtricitabine sulfoxide) is a major degradation product of Emtricitabine. Emtricitabine is a potent nucleoside reverse transcriptase inhibitor used for the treatment of HIV infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emtricitabine-15N,D2

(BW1592-15N,D2)

Cat. No.: HY-17427S

Emtricitabine-15N,D2 (BW1592-15N,D2) is a 15N-labeled and deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (**NRTI**) with an EC_{50} of 0.01 μM in PBMC cell. It is an antiviral drug for the treatment of **HIV** infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Enfuvirtide

(T20; DP178) Cat. No.: HY-P0052

Enfuvirtide (T20;DP178) is an anti-**HIV-1** fusion inhibitor peptide.

Purity: 99.56%
Clinical Data: Launched
Size: 5 mg, 10 mg

Enfuvirtide acetate

(T20 acetate; DP178 acetate) Cat. No.: HY-P0052A

Enfuvirtide (T20; DP178) acetate is an anti-**HIV-1** fusion inhibitor peptide.



Purity: 97.22%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg

Epicoccone B

Cat. No.: HY-N10294

Epicoccone B, firstly reported from C. globosum, exhibits the DPPH free radical scavenging ability with IC_{50} value of 10.8 μM, and has potent α-glucosidase inhibition with IC_{50} value of 27.3 μM. Anti-HIV activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Erythromycin Ethylsuccinate

(Erythromycin ethyl succinate; EES) Cat. No.: HY-B0957

Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against **HIV-1**.



Purity: >98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg

Erythromycin ethylsuccinate-13C,d3

(Erythromycin ethyl succinate-13C,d3; EES-13C,d3) Cat. No.: HY-B0957S

Erythromycin ethylsuccinate-13C,d3 is the 13C- and deuterium labeled. Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Etravirine

(R165335; TMC125) Cat. No.: HY-90005

Etravirine is a non-nucleoside reverse transcriptase inhibitor (**NNRTI**) used for the treatment of HIV.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Etravirine D4

(TMC-125 D4; R-165335 D4) Cat. No.: HY-90005S

Etravirine D4 (TMC-125 D4) is the deuterium labeled Etravirine. Etravirine is a non-nucleoside reverse transcriptase inhibitor (**NNRTI**) used for the treatment of HIV.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Etravirine-d8

Cat. No.: HY-132508S

Etravirine-d8 (R165335-d8) is the deuterium labeled Etravirine. Etravirine (R165335) is a non-nucleoside reverse transcriptase inhibitor (**NNRTI**) used for the treatment of HIV.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Fangchinoline

Cat. No.: HY-N1372A

Fangchinoline is isolated from Stephania tetrandra with extensive biological activities, such as enhancing immunity, anti-inflammatory sterilization and anti-atherosclerosis.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Fasudil Hydrochloride

(HA-1077 Hydrochloride; AT-877 Hydrochloride) Cat. No.: HY-10341

Fasudil Hydrochloride (HA-1077 Hydrochloride; AT877 Hydrochloride), is a nonspecific **RhoA/ROCK** inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC_{50}s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

FC131

Cat. No.: HY-P1104

FC131 is a potent **CXCR4** antagonist. FC131 inhibits [^{125}I]-SDF-1 binding to CXCR4 with an **IC_{50}** of 4.5 nM. FC131 has anti-HIV activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

FC131 TFA

Cat. No.: HY-P1104A

FC131 TFA is a **CXCR4** antagonist, inhibits [^{125}I]-SDF-1 binding to CXCR4, with an **IC_{50}** of 4.5 nM. Anti-**HIV** activity.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

FGI-106

Cat. No.: HY-124618

FGI-106 is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 is active against **Ebola**, **Rift Valley** and **Dengue Fever viruses** with **EC_{50}**s of 100 nM, 800 nM and 400-900 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGI-106 tetrahydrochloride

Cat. No.: HY-124618A

FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against **Ebola**, **Rift Valley** and **Dengue Fever viruses** with **EC_{50}**s of 100 nM, 800 nM and 400-900 nM, respectively.



Purity: 99.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Fipravirimat

Cat. No.: HY-145569

Fipravirimat is a potent **HIV-1** inhibitor. Fipravirimat has the potential for HIV and AIDS research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flavopiridol

(HMR-1275; Alvocidib; L86-8275)

Cat. No.: HY-10005

Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of **CDKs**, inhibiting CDK1, CDK2, CDK4 with **IC_{50}**s of 30, 170, 100 nM, respectively.



Purity: 99.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Flavopiridol Hydrochloride (Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride)

Cat. No.: HY-10006

Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of **CDK**, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with **IC_{50}**s of 30, 170, 100 nM, respectively.



Purity: 98.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FNC-TP

Cat. No.: HY-139262

FNC-TP is the intracellular active form of FNC. FNC is a potent **nucleoside reverse transcriptase inhibitor (NRTI)**, with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

FNC-TP trisodium

Cat. No.: HY-139262A

FNC-TP trisodium is the intracellular active form of FNC. FNC is a potent **nucleoside reverse transcriptase inhibitor (NRTI)**, with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Formycin A

(NSC 102811)

Cat. No.: HY-102026

Formycin A (NSC 102811), a purine nucleoside antibiotic, is a potent **human immunodeficiency virus type 1 (HIV-1)** inhibitor with an **EC_{50}** of 10 μM. Formycin A shows antitumor and antiviral activities.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Fosamprenavir

(Amprenavir phosphate; GW 433908) Cat. No.: HY-78726

Fosamprenavir (Amprenavir phosphate;GW 433908) is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility. Anti-**HIV** infection.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg

Fosamprenavir Calcium Salt

(GW433908G) Cat. No.: HY-17431

Fosamprenavir Calcium Salt (GW433908G) is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility. Anti-**HIV** infection.



Purity: 98.25%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Fosamprenavir-d4

(Amprenavir phosphate-d4; GW 433908-d4) Cat. No.: HY-78726S

Fosamprenavir-d4 is deuterium labeled Fosamprenavir. Fosamprenavir (Amprenavir phosphate;GW 433908) is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility. Anti-HIV infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fostemsavir

(BMS-663068) Cat. No.: HY-15440A

Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets **HIV-1** gp120 and prevents its binding to CD4$^+$ T cells.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg

Fostemsavir Tris

(BMS-663068 Tris) Cat. No.: HY-15440B

Fostemsavir Tris (BMS-663068 (Tris)) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir Tris (BMS-663068 (Tris)) is a novel attachment inhibitor that targets **HIV-1** gp120 and prevents its binding to CD4$^+$ T cells.



Purity: 98.21%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg

Fozivudine tidoxil

(BM-211290) Cat. No.: HY-126781

Fozivudine tidoxil (BM-211290) is an orally active thioether lipid-zidovudine (ZDV) conjugate with **anti-HIV** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fumagillin

(Amebacilin; NSC9168) Cat. No.: HY-B0751

Fumagillin(NSC9168) is an antimicrobial compound first isolated in 1949 from the fungus Aspergillus fumigatu. Fumagillin can inhibits **HIV1** infection through the inhibition of HIV-1 viral protein R (Vpr) activity.



Purity: 95.06%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Fuscin

Cat. No.: HY-111321

Fuscin, a fungal metabolite, **CCR5 receptor** antagonist with anti-HIV effects. Fuscin is a **respiration** and **oxidative phosphorylation** inhibitor, and also a mitochondrial SH-dependent transport-linked functions inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gardiquimod

Cat. No.: HY-103697

Gardiquimod, an imidazoquinoline analog, is a **TLR7/8** agonist. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 when used at concentrations below 10μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gardiquimod diTFA

Cat. No.: HY-103697A

Gardiquimod diTFA, an imidazoquinoline analog, is a **TLR7/8** agonist. Gardiquimod diTFA could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 when used at concentrations below 10μM.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GCA-186

Cat. No.: HY-116528

GCA-186 is a potent **anti-HIV-1** agent. GCA-186 is highly active against both wild type and mutated HIV-1 strains with EC_{50}s of 1, 180, 1, and 40 nM for III_B, $III_{B\text{-}R(Y181C)}$, NL4-3 and NL4-3$_{K103N}$ of HIV-1 strains, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glabranine

Cat. No.: HY-N3942

Glabranine, an flavonoid, is isolated from Tephrosia s.p, exerts a inhibitory effect in vitro on the dengue virus. Glabranine forms interaction with the soluble ectodomain of DENV type 2 (**DENV2**) E protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Gomisin G

Cat. No.: HY-N0858

Gomisin G is an ethanolic extract of the stems of Kadsura interior; exhibits potent anti-HIV activity with EC50 and therapeutic index (TI) values of 0.006 microgram/mL and 300, respectively.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Gomisin M2

((+)-Gomisin M2)

Cat. No.: HY-N3963

Gomisin M2 ((+)-Gomisin M2) is a lignan isolated from the fruits of Schisandra rubriflora with anti-**HIV** activity (EC_{50} of 2.4 μM). Gomisin M2 exhibits anti-cancer and anti-allergic activities and has the potential for Alzheimer's disease research.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg

gp120-IN-1

Cat. No.: HY-144730

gp120-IN-1 (compound 4e) is a potent **HIV-1 gp120** inhibitor with an IC_{50} of 2.2 μM and CC_{50} of 100.90 μM. gp120-IN-1 shows anti-HIV-1 activity. gp120-IN-1 shows cytotoxicity in a dose dependent manner in SUP-T1 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

gp120-IN-2

Cat. No.: HY-144731

gp120-IN-2 (compound 4i) is a potent **HIV-1 gp120** inhibitor with an IC_{50} of 7.5 μM and CC_{50} of 112.93 μM. gp120-IN-2 shows anti-HIV-1 activity. gp120-IN-2 shows cytotoxicity in a dose dependent manner in SUP-T1 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GPI-1046

Cat. No.: HY-124619

GPI-1046 is a immunophilin ligand without antibiotic action and attenuates ethanol intake in part through the upregulation of **glutamate transporter 1 (GLT1)** in PFC and NAc-core.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GPS491

Cat. No.: HY-139850

GPS491 (EC_{50} = 0.47 μM) suppresses expression of the **HIV-1** structural protein Gag and alters HIV-1 RNA accumulation, decreasing the abundance of RNAs encoding the structural proteins while increasing levels of viral RNAs encoding the regulatory proteins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK2838232

Cat. No.: HY-15884

GSK2838232 inhibit HIV reverse transcriptase activity across a broad panel of HIV-1 isolates, extracted from patent WO/2013090664A1, compound51.



Purity: 99.34%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK3532795

(BMS-955176)

Cat. No.: HY-112714

GSK3532795 (BMS-955176) is a potent, orally active, second-generation **HIV-1** maturation inhibitor, with EC_{50}s of 1.9, 10.2, 2.7 and 13 nM for HIV-1 WT, HIV-1 WT(human serum), HIV-1 V370A, and HIV-1 ΔV370, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Hck-IN-1

Cat. No.: HY-125028

Hck-IN-1 (compound B9), a diphenylpyrazolo compound, is a selective **Nef-dependent Hck** inhibitor with **IC_{50}**s of 2.8 μM, >20 μM for Nef:Hck complex and Hck, respectively.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HIV p17 Gag (77-85)

Cat. No.: HY-P1757

HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 inhibitor-10

Cat. No.: HY-142253

HIV-1 inhibitor-10 is a nanomolar **HIV-1** maturation inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 inhibitor-11

Cat. No.: HY-142467

HIV-1 inhibitor-11, a fused pyridine ring derivative, is a HIV-1 inhibitor. WO2021104413A1 (compound 1-1b).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 inhibitor-12

Cat. No.: HY-142468

HIV-1 inhibitor-12 is potent **HIV-1** inhibitor. HIV-1 inhibitor-12 inhibits HIV-1 capsid protein polymerization with an IC_{50} of 9 nM (WO2021104413A1, compound 1-1a).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 inhibitor-19

Cat. No.: HY-146746

HIV-1 inhibitor-19 is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor (**NNRTI**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 inhibitor-20

Cat. No.: HY-146753

HIV-1 inhibitor-20 is a potent **HIV-1** inhibitor by non-classical isosteric replacement of amide to 1,2,4-oxadiazoles.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 inhibitor-3

Cat. No.: HY-128722

HIV-1 inhibitor-3 is a **HIV** infection inhibitor extracted from patent US2018360927.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 inhibitor-30

Cat. No.: HY-146365

HIV-1 inhibitor-30 (compound 10i) is a potent **HIV-1** inhibitor with an **EC_{50}** value of 40 nM and an **IC_{50}** value of 80 nM for HIV-1 RT DNA polymerase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 inhibitor-8

Cat. No.: HY-132291

HIV-1 inhibitor-8 is an orally active, low-toxicity and potent **HIV1** non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV-1 inhibitor-8 yields exceptionally potent antiviral activities (**EC_{50}**=4.44~54.5 nM) against various **HIV1** strains.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 inhibitor-9

Cat. No.: HY-139631

HIV-1 inhibitor-9 is found to be potent inhibitor against the wild-type (WT) **HIV-1** strain or multiple NNRTI-resistant strains at low nanomolar levels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 integrase inhibitor

Cat. No.: HY-13025

HIV-1 integrase inhibitor is uesful for anti-HIV.



Purity: 96.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

HIV-1 integrase inhibitor 3

Cat. No.: HY-108817

HIV-1 integrase inhibitor 3 is a **HIV-1 integrase strand transfer** (**INST**) inhibitor with an IC_{50} of 2.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 integrase inhibitor 4

Cat. No.: HY-108820

HIV-1 integrase inhibitor 4 is a **HIV-1 integrase strand transfer** (**INST**) inhibitor with an IC_{50} of 3.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 integrase inhibitor 9

Cat. No.: HY-132572

HIV-1 integrase inhibitor 9 (compound 8a) is a potent **HIV-1 RNase H** inhibitor with an IC_{50} of 12.3 μM. HIV-1 integrase inhibitor 9 shows an antiviral activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 Nef-IN-1

Cat. No.: HY-138562

HIV-1 Nef-IN-1 is an **HIV-1 Nef** protein inhibitor that efficiently competes for Nef-SH3Hck interactions with a K_d of 6.7 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HIV-1 Rev (34-50)

(HIV-1 rev Protein (34-50))

Cat. No.: HY-P1586

HIV-1 Rev (34-50) is a 17-aa peptide derived from the Rev-responsive element (RRE)-binding domains of Rev in HIV-1, with anti-HIV-1 activity.

TRQARRNRRRRWRERQR

Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg, 5 mg

Hydroxyurea

(Hydroxycarbamide)

Cat. No.: HY-B0313

Hydroxyurea is a cell apoptosis inducer that inhibit **DNA** synthesis through inhibition of **ribonucleotide reductase**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Hypoglaunine D

Cat. No.: HY-N9340

Hypoglaunine D is an analogue of Triptonine B and acts as an **anti-HIV** compound. Hypoglaunine D inhibits **HIV** replication in H9 lymphocytes with an EC_{50} value of 22 μg/ml.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ibalizumab

(TMB-355; TNX-355)

Cat. No.: HY-P99028

Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents **HIV** cell entry by binding to <B>CD4 receptor. Ibalizumab has the potential for HIV-1 infection research.

Ibalizumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Icariside D2

Cat. No.: HY-N7450

Icariside D2, isolated from Annona glabra fruit, inhibits **angiotensin-converting enzyme**. Icariside D2 shows significant cytotoxic activity on the HL-60 cell line with the **IC_{50}** value of 9.0 ± 1.0 μM. Icariside D2 induces apoptosis .



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ilimaquinone

Cat. No.: HY-119500

Ilimaquinone, a marine sponge metabolite, displays anticancer activity via GADD153-mediated pathway. Ilimaquinone can induce vesiculation of the Golgi apparatus. Ilimaquinone exerts anti-HIV, anti-microbial, anti-inflammatory, and effects.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 100 μg

IMB-301

Cat. No.: HY-122156

IMB-301 is a specific **HIV-1 replication** inhibitor that binds to **hA3G (human APOBEC3G)**, interrupts the hA3G-Vif interaction and inhibits Vif-mediated degradation of hA3G. IMB-301 inhibits the replication of HIV-1 in H9 cells (IC_{50}=8.63 uM).



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Indinavir

(MK-639; L-735524)

Cat. No.: HY-B0689

Indinavir(MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Indinavir sulfate

(MK-639 sulfate; L735524 sulfate)

Cat. No.: HY-B0689A

Indinavir sulfate(MK-639 sulfate; L735524 sulfate) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability. Indinavir sulfate is also a **SARS-CoV 3CL^{pro}** inhibitor with an **IC_{50}** of 1.71 μM.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Indinavir-d6

Cat. No.: HY-B0689S

Indinavir-d6 is the deuterium labeled Indinavir. Indinavir (MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Inosine pranobex

(Imunovir; Delimmun; Groprinosin;)

Cat. No.: HY-107801

Inosine pranobex is a potent, broad-spectrum antiviral compound for **HIV** infection. Inosine pranobex is an immunopotentiator.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg

Integracin B

Cat. No.: HY-N7330

Integracin B is a potent dimeric alkyl aromatic inhibitor of **HIV-1 integrase** discovered from the screening of fungal extracts using an in vitro assay. Integracin B inhibits both coupled and strand transfer activity of HIV-1 integrase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

InteriotherinA

Cat. No.: HY-N6849

Interiotherin A is a lignan with a dibenzocyclooctadiene skeleton isolated from Kadsura interior. Interiotherin A inhibits **HIV** replication to exhibit anti-HIV activity, it has a role as a metabolite and an anti-HIV agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

IQP-0528

Cat. No.: HY-19509

IQP-0528 is a highly potent **nonnucleoside reverse transcriptase inhibitor** (NNRTI). IQP-0528 shows nanomolar activity against both HIV-1 and HIV-2, with an HIV-1 EC_{50} of 0.2 nM and an HIV-2 EC_{50} of 100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Islatravir

(MK-8591)

Cat. No.: HY-104012

Islatravir (MK-8591) is a potent anti-**HIV-1** agent, acting as a nucleoside **reverse transcriptase** inhibitor, with EC_{50}s of 0.068 nM, 3.1 nM and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IT1t

Cat. No.: HY-101458

IT1t is a potent **CXCR4** antagonist; inhibits CXCL12/CXCR4 interaction with an IC_{50} of 2.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IT1t dihydrochloride

Cat. No.: HY-101458A

IT1t dihydrochloride is a potent **CXCR4** antagonist; inhibits CXCL12/CXCR4 interaction with an IC_{50} of 2.1 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ivermectin

(MK-933)

Cat. No.: HY-15310

Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of **Impα/β1-mediated nuclear import** and has potent antiviral activity towards both HIV-1 and dengue virus.



Purity: 96.79%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Kaempferol

(Kempferol; Robigenin)

Cat. No.: HY-14590

Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits **estrogen receptor α** expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

KRH-3955 hydrochloride

Cat. No.: HY-122058A

KRH-3955 hydrochloride is an orally bioavailable **CXCR4** antagonist. KRH-3955 hydrochloride inhibits SDF-1α binding to **CXCR4** with an IC_{50} of 0.61 nM. KRH-3955 hydrochloride is also a highly potent and selective inhibitor of **X4 HIV-1**, with an EC_{50} of 0.3 to 1.0 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Chicoric Acid

((-)-Chicoric acid; trans-Caffeoyltartaric acid)

Cat. No.: HY-N0457A

L-Chicoric Acid ((-)-Chicoric acid) is a dicaffeoyltartaric acid and a potent, selective and reversible **HIV-1 integrase** inhibitor with an IC_{50} of ~100 nM. L-Chicoric Acid inhibits **HIV-1** replication in tissue culture.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mg

L-Cycloserine

((S)-Cycloserine; (S)-4-Amino-3-isoxazolidone)

Cat. No.: HY-B1122

L-Cycloserine ((S)-4-Amino-3-isoxazolidone) irreversibly inhibits GABA pyridoxal 5′-phosphate-dependent aminitransferase in E.



Purity: 99.13%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

Lamivudine

(BCH-189)

Cat. No.: HY-B0250

Lamivudine (BCH-189) is a **nucleoside reverse transcriptase inhibitors (NRTIs)**. Lamivudine (BCH-189) can inhibit **HIV reverse transcriptase 1/2** and also the reverse transcriptase of **hepatitis B virus**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Lamivudine 13C,15N2

Cat. No.: HY-135330

Lamivudine 13C,15N2 is a labelled impurity of Lamivudine (BCH-189). Lamivudine is a nucleoside reverse transcriptase inhibitors (NRTIs), and can inhibit HIV reverse transcriptase 1/2 and the reverse transcriptase of hepatitis B virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LEDGIN6

(CX05168; CX04328) Cat. No.: HY-10522

LEDGIN6 (CX05168) is a quinoline-based protein-protein interaction inhibitor of **LEDGF/p75** and **HIV integrase**.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lenacapavir

(GS-6207) Cat. No.: HY-111964

Lenacapavir (GS-6207) is a **HIV-1 capsid** inhibitor. Lenacapavir shows anti-HIV activity with an EC_{50} of 100 pM in MT-4 cells. Lenacapavir displays a mean EC_{50} of 50 pM (20-160 pM) against 23 HIV-1 clinical isolates from different subtypes in peripheral blood mononuclear cells (PBMCs).



Purity: 98.49%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Leptomycin A

Cat. No.: HY-N6795

Leptomycin A, a Streptomyces metabolite, is an inhibitor of **CRM1 (exportin 1)** that blocks CRM1 interaction with nuclear export signals, preventing the nuclear export of a broad range of proteins. Leptomycin A suppresses HIV-1 replication. Less potent than Leptomycin B.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lersivirine

(UK-453061) Cat. No.: HY-14267

Lersivirine (UK-453061) is potent and selective **non-nucleoside reverse transcription** inhibitor (NNRTI; IC_{50}=119 nM) with excellent efficacy against NNRTI-resistant viruses.



Purity: 98.33%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Letrazuril

Cat. No.: HY-106859

Letrazuril is an **anti-HIV** agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Limonin

(Limonoic acid 3,19:16,17 dilactone) Cat. No.: HY-17411

Limonin is a triterpenoid enriched in citrus fruits, which has antivirus and antitumor ability. IC50 Value: Target: HIV; anticancer Limonin is a triterpenoid aglycone that is a bitter principle of citrus fruits.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

Lopinavir

(ABT-378) Cat. No.: HY-14588

Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease**, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Lopinavir-d8

Cat. No.: HY-14588S1

Lopinavir-d8 (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the **HIV-1 protease**, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Loviride

(R 89439) Cat. No.: HY-15355

Loviride (R 89439) is a non-nucleoside reverse transcriptase inhibitor (**NNRTI**), with an IC_{50} of 0.3 μM for **reverse transcriptase** from **HIV-1**. Loviride (R 89439) inhibits HIV-1, HIV-2 and SIV replication in MT-4 cells.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Maraviroc

(UK-427857) Cat. No.: HY-13004

Maraviroc (UK-427857) is a selective **CCR5** antagonist with activity against human **HIV**.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Maraviroc-d6

Cat. No.: HY-13004S

Maraviroc-d6 (UK-427857-d6) is the deuterium labeled Maraviroc. Maraviroc (UK-427857) is a selective **CCR5** antagonist with activity against human **HIV**.



Purity: >98%
Clinical Data:
Size: 500 μg, 1 mg, 5 mg, 10 mg, 50 mg

Maslinic acid

(Crategolic acid; 2α-Hydroxyoleanolic acid)

Cat. No.: HY-N0629

Maslinic acid can inhibit the DNA-binding activity of **NF-κB p65** and abolish the phosphorylation of **IκB-α**, which is required for p65 activation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Mavorixafor

(AMD-070)

Cat. No.: HY-50101

Mavorixafor (AMD-070) is a potent, selective and orally available **CXCR4** antagonist, with an IC_{50} value of 13 nM against CXCR4 ^{125}I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC_{50} of 1 and 9 nM, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Mavorixafor trihydrochloride

(AMD-070 trihydrochloride)

Cat. No.: HY-50101A

Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available **CXCR4** antagonist, with an IC_{50} value of 13 nM against CXCR4 ^{125}I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with...



Purity: 98.69%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Megestrol acetate

Cat. No.: HY-13676

Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol **androgen receptors** human BPH tissue.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Megestrol acetate-d3

Cat. No.: HY-13676S

Megestrol acetate-d3 is the deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Megestrol acetate-d3-1

Cat. No.: HY-13676S1

Megestrol acetate-d3-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Melliferone

Cat. No.: HY-N8701

Melliferone is a triterpenoid found in Brazilian propolis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Methyl gallate

(Gallincin; NSC 363001)

Cat. No.: HY-N2010

Methyl gallate is a plant phenolic with antioxidant, anticancer, and anti-inflammatory activities. Methyl gallate also shows **bacterial** inhibition activity. Methyl gallate also has anti-**HIV-1** and **HIV-1** enzyme inhibitory activities.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 5 g

Miltefosine

(HePC; Hexadecyl phosphocholine)

Cat. No.: HY-13685

Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the **PI3K/Akt** activity. Miltefosine is an inhibitor of **CTP-phosphocholine cytidyltransferase (CCT)**.

Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g

Miltefosine-d9

(HePC-d9; Hexadecyl phosphocholine-d9) Cat. No.: HY-13685S

Miltefosine-d9 (HePC-d9) is the deuterium labeled Miltefosine. Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the **PI3K/Akt** activity. Miltefosine is an inhibitor of **CTP-phosphocholine cytidyltransferase (CCT)**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mitoguazone

(Methylglyoxal-bis(guanylhydrazone); MGBG; Methyl-GAG) Cat. No.: HY-106634

Mitoguazone (Methylglyoxal-bis(guanylhydrazone)) is a synthetic polycarbonyl derivative with potent antineoplastic activity.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MIV-150

(PC 815) Cat. No.: HY-19378

MIV-150 is a nonnucleoside reverse transcriptase (**NNRT**) inhibitor, blocking HIV-1 and HIV-2 infections, with an EC_{50}<1 nM against HIV-1/HIV-2_{MN}.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-2048

Cat. No.: HY-13305

MK-2048 is a potent inhibitor of integrase and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively. IC50 Value: 2.6 nM for HIV Integrase Target: HIV Integrase MK-2048 is a second generation integrase inhibitor, intended to be used against HIV infection.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

MPG, HIV related

Cat. No.: HY-P1566

MPG, HIV related is 27-aa peptide, derived from both the nuclear localisation sequence of SV40 large T antigen and the fusion peptide domain of HIV-1 gp41 and is a potent delivery agent for the generalised delivery of nucleic acids and of oligonucleotides into cultured cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MS417

(GTPL7512) Cat. No.: HY-111139

MS417 is a selective BET-specific **BRD4** inhibitor, binds to BRD4-BD1 and BRD4-BD2 with IC_{50}s of 30, 46 nM and K_ds of 36.1, 25.4 nM, respectively, with weak selectivity at CBP BRD (IC_{50}, 32.7 μM).



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NBD-14189

Cat. No.: HY-139985

NBD-14189 is a potent **HIV-1** entry antagonist with an IC_{50} of 89 nM against the HIV-1_{HXB2} pseudovirus. NBD-14189 binds to HIV-1 gp120 and shows potent antiviral activity (EC_{50}<200 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NBD-14270

Cat. No.: HY-139989

NBD-14270, a pyridine analogue, is a potent **HIV-1** entry antagonist with an IC_{50} of 180 nM against 50 HIV-1 Env-pseudotyped viruses. NBD-14270 binds to HIV-1 gp120 and shows potent antiviral activity. NBD-14270 shows low cytotoxicity (CC_{50}>100 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NBD-556

Cat. No.: HY-76648

NBD-556, a CD4 mimetic, is a potent **HIV-1** entry inhibitor that blocks the gp120-CD4 interaction. NBD-556 shows potent cell fusion and virus-cell fusion inhibitory activity at low micromolar levels.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

NBD-557

Cat. No.: HY-76649

NBD-557 is a potentially HIV-1 inhibitor.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Nelfinavir

(AG1341) Cat. No.: HY-15287

Nelfinavir (AG-1341) is a potent and orally bioavailable **HIV-1 protease** inhibitor (K_i=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent.



Purity: 96.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Nelfinavir Mesylate

(AG 1343 Mesylate) Cat. No.: HY-15287A

Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable **HIV-1 protease** inhibitor (K_i=2 nM) for HIV infection. Nelfinavir Mesylate (AG 1343 Mesylate) is a broad-spectrum, anticancer agent.



Purity: 99.07%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Nelfinavir-d3

Cat. No.: HY-15287S

Nelfinavir-d3 (AG1341-d3) is the deuterium labeled Nelfinavir. Nelfinavir (AG-1341) is a potent and orally bioavailable **HIV-1 protease** inhibitor (K_i=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Nevirapine

(BI-RG 587; NSC 641530; NVP) Cat. No.: HY-10570

Nevirapine is a non-nucleoside inhibitor of **HIV-1** reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM.



Purity: 99.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Nevirapine-d3

Cat. No.: HY-10570S1

Nevirapine-d3 (BI-RG 587-d3) is the deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of **HIV-1** reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

Nevirapine-D4

Cat. No.: HY-10570S

Nevirapine-D4 is deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of **HIV-1** reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NF279

Cat. No.: HY-D0976

NF279 is a potent selective and reversible **P2X1 receptor** antagonist, with an IC_{50} of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC_{50}=1.62 μM), P2X4 (IC_{50}>300 μM).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nifeviroc

Cat. No.: HY-111069

Nifeviroc is an orally active **CCR5** antagonist. Nifeviroc is used for the study of HIV type-1 infection.
.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nigranoic acid

Cat. No.: HY-122935

Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits **HIV-1 reverse transcriptase**. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Obefazimod

(ABX464) Cat. No.: HY-100870

Obefazimod (ABX464) is a potent **anti-HIV** agent. Obefazimod inhibits **HIV-1** replication in stimulated peripheral blood mononuclear cells (PBMCs) with an IC_{50} ranging between 0.1 μM and 0.5 μM.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Oleanolic Acid

(Oleanic acid; Caryophyllin) Cat. No.: HY-N0156

Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Oleanonic acid

(3-Oxooleanolic acid) Cat. No.: HY-N1487

Oleanonic acid (3-Oxooleanolic acid) is a triterpenoid, inhibits infection by HIV-1 in in vitro infected PBMC, naturally infected PBMC and monocyte/macrophages with **EC_{50}** of 22.7 mM, 24.6 mM and 57.4 mM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

Oltipraz

(RP 35972; NSC 347901) Cat. No.: HY-12519

Oltipraz has an inhibitory effect on **HIF-1α** activation in a time-dependent manner, completely abrogating **HIF-1α** induction at ≥10 μM concentrations, the **IC_{50}** of Oltipraz for **HIF-1α** inhibition is 10 μM. Oltipraz is a potent **Nrf2** activator.



Purity: 99.74%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Oltipraz-d3

(RP 35972-d3; NSC 347901-d3) Cat. No.: HY-12519S

Oltipraz-d3 (RP 35972-d3) is the deuterium labeled Oltipraz. Oltipraz has an inhibitory effect on **HIF-1α** activation in a time-dependent manner, completely abrogating **HIF-1α** induction at ≥10 μM concentrations, the **IC_{50}** of Oltipraz for **HIF-1α** inhibition is 10 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ONX-0914

(PR-957) Cat. No.: HY-13207

ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 **(LMP7)**, the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ONX-0914 TFA

(PR-957 TFA) Cat. No.: HY-13207A

ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 **(LMP7)**, the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Ophiobolin C

(Zizanin A) Cat. No.: HY-123902

Ophiobolin C inhibits CCR5 binding to the envelop protein gp120 and CD4, which is responsible for mediating the entry of HIV-1 into cells. Ophiobolin C is also cytotoxic to chronic lymphocytic leukemia cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oxindole

(Indolin-2-one) Cat. No.: HY-Y0061

Oxindole (Indolin-2-one) is an aromatic heterocyclic building block. 2-indolinone derivatives have become lead compounds in the research of kinase inhibitors.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Panobinostat

(LBH589; NVP-LBH589) Cat. No.: HY-10224

Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective **HDAC** inhibitor, and has antineoplastic activities.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Panobinostat-d4

(LBH589-d4; NVP-LBH589-d4) Cat. No.: HY-10224S

Panobinostat-d4 (LBH589-d4) is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective **HDAC** inhibitor, and has antineoplastic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Panobinostat-d4 hydrochloride

(LBH589-d4 hydrochloride; NVP-LBH589-d4 hydrochloride) Cat. No.: HY-10224S1

Panobinostat-d4 (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Peldesine

(BCX 34) Cat. No.: HY-106934

Peldesine (BCX 34) is a potent, competitive, reversible and orally active **purine nucleoside phosphorylase (PNP)** inhibitor with IC_{50}s of 36 nM, 5 nM, and 32 nM for **human, rat, and mouse red blood cell (RBC) PNP**, respectively.



Purity: >98%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

Peldesine dihydrochloride

(BCX 34 dihydrochloride) Cat. No.: HY-106934A

Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active **purine nucleoside phosphorylase (PNP)** inhibitor with IC_{50}s of 36 nM, 5 nM, and 32 nM for **human, rat, and mouse red blood cell (RBC) PNP**, respectively.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Pentosan Polysulfate

Cat. No.: HY-A0203

Pentosan Polysulfate is an orally bioavailable medication with anti-inflammatory and pro-chondrogenic properties. Pentosan Polysulfate also displays a potent and selective anti-**HIV** activity. Pentosan Polysulfatecan be used for the research of interstitial cystitis.

Purity: >98%
Clinical Data: Launched
Size: 100 mg

Pentosan Polysulfate Sodium (W/W 43%)

Cat. No.: HY-A0203A

Pentosan Polysulfate Sodium is an orally bioavailable, semi-synthetic medication with anti-inflammatory and pro-chondrogenic properties. Pentosan Polysulfate Sodium also is a potent and selective anti-**HIV** agent.

Purity: >98%
Clinical Data: Launched
Size: 100 mg

Pentoxifylline

(BL-191; PTX; Oxpentifylline) Cat. No.: HY-B0715

Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective **phosphodiesterase (PDE)** inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects.



Purity: 99.35%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g

Pentoxifylline-4',4',6',6',6'-d5

Cat. No.: HY-B0715S2

Pentoxifylline-4',4',6',6',6'-d5 is the deuterium labeled Pentoxifylline.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pentoxifylline-d6

Cat. No.: HY-B0715S

Pentoxifylline-d6 (BL-191-d6) is the deuterium labeled Pentoxifylline.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Peptide T

Cat. No.: HY-P0272

Peptide T is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the **CD4** receptor and prevents binding of **HIV** to the CD4 receptor.



Purity: 99.51%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

Peptide T TFA

Cat. No.: HY-P0272A

Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the **CD4** receptor and prevents binding of **HIV** to the CD4 receptor.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg

Peritassine A

Cat. No.: HY-N3510

Peritassine A, an alkaloid that could be isolated from Tripterygium wilfordii Hook. f., possesses anti-HIV activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PF-3450074

(PF-74)

Cat. No.: HY-120072

PF-3450074 (PF-74) is a specifical inhibitor of **HIV-1 capsid protein (CA)** and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC_{50}=8-640 nM).



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pirmitegravir

Cat. No.: HY-130000

Pirmitegravir is a potent and first-in-class inhibitor of **allosteric integrase** (**ALLINI**) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC_{50} in human PBMCs with a >24,000 therapeutic index against HIV-1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKF050-638

Cat. No.: HY-114597

PKF050-638 is a potent and selective inhibitor of **HIV-1 Rev** (IC_{50}=0.04 μM). PKF050-638 inhibits the CRM1-mediated Rev nuclear export by disrupting **CRM1-NES** interaction.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Plerixafor

(AMD 3100; JM3100; SID791)

Cat. No.: HY-10046

Plerixafor (AMD 3100) is a selective **CXCR4** antagonist with an IC_{50} of 44 nM. Plerixafor, an immunostimulant and a **hematopoietic stem cell (HSC)** mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits **HIV-1** and **HIV-2** replication with an EC_{50} of 1-10 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Plerixafor octahydrochloride (AMD3100 octahydrochloride; JM3100 octahydrochloride; SID791 octahydrochloride)

Cat. No.: HY-50912

Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective **CXCR4** antagonist with an IC_{50} of 44 nM.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Plerixafor-d4

Cat. No.: HY-10046S

Plerixafor-d4 is the deuterium labeled Plerixafor. Plerixafor (AMD 3100) is a selective **CXCR4** antagonist with an IC_{50} of 44 nM. Plerixafor, an immunostimulant and a **hematopoietic stem cell (HSC)** mobilizer, is an allosteric agonist of CXCR7.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PMEDAP

Cat. No.: HY-106382

PMEDAP is a potent inhibitor of human immunodeficiency virus **(HIV)** replication. PMEDAP has anti-murine cytomegalovirus (MCMV) activity. PMEDAP is a very potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PNU-103017

Cat. No.: HY-19236

PNU-103017 is an **HIV protease** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pradimicin A

Cat. No.: HY-132191

Pradimicin A (PRM-A) is a potent antifungal agent, with an **MIC** of 4 μg/mL against Candida rugosa. Pradimicin A has antiviral activities against CoV, HIV and other enveloped viruses. Pradimicin A shows aggregation property, and can recognize d-Man in the presence of Ca^{2+} ion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Probenecid

Cat. No.: HY-B0545

Probenecid is a potent and selective agonist of transient receptor potential vanilloid 2 (**TRPV2**) channels. Probenecid also inhibits **pannexin 1** channels.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

Probenecid-d14

Cat. No.: HY-B0545S

Probenecid-d14 is the deuterium labeled Probenecid. Probenecid is a potent and selective agonist of transient receptor potential vanilloid 2 (**TRPV2**) channels. Probenecid also inhibits **pannexin 1** channels.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Pseudohypericin

Cat. No.: HY-N0685

Pseudohypericin and its congener Hypericin are the major hydroxylated phenanthroperylenediones present in Hypericum species. Pseudohypericin shows anti-HIV activity.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pseudothymidine

(5-Methyl-2'-Deoxypseudouridin)

Cat. No.: HY-101969

Pseudothymidine is a C-nucleoside analog of thymidine.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Psoralen

(Ficusin)

Cat. No.: HY-N0053

Psoralen (Ficusin) is a coumarin isolated from the seeds of Fructus Psoraleae. Psoralen exhibits a wide range of biological properties, including anti-cancer, antioxidant, antidepressant, anticancer, antibacterial, and antiviral, et al.



Purity: 99.92%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PTACH

(NCH-51)

Cat. No.: HY-12954

PTACH (NCH-51) is a potent **HDAC** inhibitor with IC_{50}s of 48 nM, 32 nM, and 41 nM for **HDAC1**, **HDAC4**, and **HDAC6**, respectively. PTACH exerts potent growth inhibition against various cancer cells (EC_{50}s of 1.1-9.1 μM) .



Purity: 99.65%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Q-VD-OPh

(QVD-OPH; Quinoline-Val-Asp-Difluorophenoxymethylketone)

Cat. No.: HY-12305

Q-VD-OPh is an irreversible **pan-caspase** inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC_{50} of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh can inhibits **HIV** infection. Q-VD-OPh is able to cross the blood-brain barrier.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Raltegravir

(MK-0518)

Cat. No.: HY-10353

Raltegravir is a potent **integrase (IN)** inhibitor, used to treat HIV infection.



Purity: 99.53%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Raltegravir potassium

(MK 0518 potassium)

Cat. No.: HY-10353A

Raltegravir (MK 0518) potassium is a potent **integrase (IN)** inhibitor, used to treat HIV infection.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Raltegravir-d3 potassium

(MK 0518-d3 potassium)

Cat. No.: HY-10353AS

Raltegravir-d3 potassium (MK 0518-d3 potassium) is the deuterium labeled Raltegravir potassium. Raltegravir (MK 0518) potassium is a potent **integrase (IN)** inhibitor, used to treat HIV infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Raltegravir-d4

Cat. No.: HY-10353S

Raltegravir-d4 is deuterium labeled Raltegravir. Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reverse transcriptase-IN-1

Cat. No.: HY-130241

Reverse transcriptase-IN-1 (Compound 12z), a diarylbenzopyrimidine (DABP) analogue, is a potent, orally active **HIV-1 nonnucleoside reverse transcriptase** inhibitor.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RIG-1 modulator 1

Cat. No.: HY-107902

RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including **influenza virus**, **HBV**, **HCV** and **HIV** extracted from patent WO 2015172099 A1.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

Rilpivirine

(R278474; TMC278; DB08864)

Cat. No.: HY-10574

Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside **reverse transcriptase** inhibitor (**NNRTI**). Rilpivirine has high antiviral activity against wild-type **HIV** (EC_{50}=0.4 nM) and mutant viruses (EC_{50}=0.1-2.0 nM).



Purity: 98.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Rilpivirine-d6

Cat. No.: HY-10574S

Rilpivirine-d6 is the deuterium labeled Rilpivirine. Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside **reverse transcriptase** inhibitor (**NNRTI**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Ritonavir

(ABT 538; RTV)

Cat. No.: HY-90001

Ritonavir (ABT 538) is an inhibitor of **HIV protease** used to treat HIV infection and AIDS. Ritonavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an IC_{50} of 1.61 μM.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Ritonavir-13C,d3

(ABT 538-13C,d3; RTV-13C,d3)

Cat. No.: HY-90001S1

Ritonavir-13C,d3 (ABT 538-13C,d3) is the 13C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of **HIV protease** used to treat HIV infection and AIDS. Ritonavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an IC_{50} of 1.61 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ritonavir-d6

Cat. No.: HY-90001S

Ritonavir-d6 (ABT 538-d6) is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of **HIV protease** used to treat HIV infection and AIDS. Ritonavir is also a **SARS-CoV 3CL^{pro}** inhibitor with an IC_{50} of 1.61 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RN-18

Cat. No.: HY-102014

RN-18 is a HIV-1 viral infectivity factor (**HIV-1 Vif**) inhibitor with an IC_{50} of 6 μM in nonpermissive H9 cells.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ro24-7429

Cat. No.: HY-19149

Ro24-7429 is a potent and orally active HIV-1 transactivator protein **Tat** antagonist. Ro24-7429 is also a **runt-related transcription factor 1 (RUNX1)** inhibitor. Ro24-7429 has anti-HIV, antifibrotic and anti-inflammatory effects.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rolipram

((R,S)-Rolipram; SB 95952; ZK 62711)

Cat. No.: HY-16900

Rolipram is a selective phosphodiesterases **PDE4** inhibitor with **IC_{50}**s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.



Purity: 99.58%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Rottlerin

(Mallotoxin; NSC 56346; NSC 94525)

Cat. No.: HY-18980

Rottlerin, a natural product purified from Mallotus Philippinensis, is a specific **PKC** inhibitor, with **IC_{50}** values for PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

Rovafovir etalafenamide

(GS-9131)

Cat. No.: HY-19851

Rovafovir etalafenamide (GS-9131), a prodrug of the adenosine nucleotide analogue GS-9148, is an orally active nucleoside reverse transcriptase inhibitor **(NRTI)**. Rovafovir etalafenamide is potent and active against a variety of NRTI mutants, and shows potent anti-HIV-1 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Salicylanilide

(2-Hydroxybenzanilide)

Cat. No.: HY-B1408

Salicylanilide demonstrates a wide range of biological activities including antiviral potency which can inhibit **HIV virus** by targeting **HIV-1 integrase** or **reverse transcriptase**.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Saquinavir

(Ro 31-8959)

Cat. No.: HY-17007

Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a **SARS-CoV $3CL^{pro}$** inhibitor with an **IC_{50}** of 1.36 μM.



Purity: 99.34%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Saquinavir Mesylate

(Ro 31-8959/003)

Cat. No.: HY-17003

Saquinavir mesylate is an HIV Protease Inhibitor used in antiretroviral therapy. IC50 Value: Target: HIV Protease Saquinavir is a protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Saquinavir-d9

Cat. No.: HY-17007S

Saquinavir-d9 (Ro 31-8959-d9) is the deuterium labeled Saquinavir. Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a **SARS-CoV $3CL^{pro}$** inhibitor with an **IC_{50}** of 1.36 μM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

SARS-CoV-IN-2

Cat. No.: HY-135856

SARS-CoV-IN-2 is an effective inhibitor of **SARS-CoV** replication. SARS-CoV-IN-2 shows anti-Coronavirus activity with an **EC_{50}** of 1.9 μM in Vero cells.



Purity: 98.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

SARS-CoV-IN-3

Cat. No.: HY-135858

SARS-CoV-IN-3 is an effective inhibitor of **SARS-CoV** replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an **EC_{50}** of 3.6 μM in Vero cells.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Schisantherin D

Cat. No.: HY-N7543

Schisantherin D is a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera. Schisantherin D shows anti-**HIV** replication activities with an **EC_{50}** of 0.5 μg/mL. Schisantherin D inhibits endothelin receptor B (ETBR) and has hepatoprotective effects.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Scutellarin

Cat. No.: HY-N0751

Scutellarin, an active flavone isolated from Scutellaria baicalensis, can down-regulates the **STAT3/Girdin/Akt** signaling in HCC cells, and inhibits RANKL-mediated **MAPK and NF-κB** signaling pathway in osteoclasts.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

Seletracetam lithium

(Ucb 44212 lithium)

Cat. No.: HY-119810A

Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a **SV2A** modulator for the research of epilepsy.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Sennoside A

Cat. No.: HY-N0365

Sennoside A is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia). Sennoside A is a **HIV-1** inhibitor effective on HIV-1 replication.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Shikonin

(C.I. 75535; Isoarnebin 4)

Cat. No.: HY-N0822

Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent **TMEM16A chloride channel** inhibitor with an IC_{50} of 6.5 μM. Shikonin is a specific **pyruvate kinase M2 (PKM2)** inhibitor and can also inhibit **TNF-α** and **NF-κB** pathway.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

SJ-3366

(IQP-0410)

Cat. No.: HY-118423

SJ-3366 (IQP-0410) is a potent inhibitor of HIV nonnucleoside reverse transcriptase. SJ-3366 (IQP-0410) inhibits HIV at sub-nanomolar concentrations primarily through a typical non-nucleoside mechanism.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sodium copper chlorophyllin B

Cat. No.: HY-B2226

Sodium copper chlorophyllin B exerts **antiviral** activities against **Influenza virus** and **HIV** with IC_{50}s of 50 to 100 μM for both of them.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g

Soyasaponin II

Cat. No.: HY-122920

Soyasaponin II is a saponin with antiviral activity. Soyasaponin II inhibits the replication of HSV-1, HCMV, influenza virus, and HIV-1. Soyasaponin II shows potent inhibition on HSV-1 replication.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 1 mg

Sparstolonin B

Cat. No.: HY-116213

Sparstolonin B acts as a selective **TLR2** and **TLR4** antagonist and selectively blocks TLR2- and TLR4-mediated inflammatory signaling. Sparstolonin B has anti-**HIV** and anticancer activities.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Stampidine

Cat. No.: HY-122470

Stampidine is a **nucleoside reverse transcriptase inhibitor (NRTI)** with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain $HTLV_{IIIB}$ (B-envelope subtype) and primary clinical isolates with IC_{50}s of 1 nM and 2 nM, respectively.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Stavudine

(d4T)

Cat. No.: HY-B0116

Stavudine (d4T) is an orally active **nucleoside reverse transcriptase** inhibitor **(NRTI)**. Stavudine has activity against **HIV-1** and **HIV-2**. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA).



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Stavudine sodium

(d4T sodium)

Cat. No.: HY-B0116A

Stavudine (d4T) sodium is an orally active **nucleoside reverse transcriptase** inhibitor **(NRTI)**. Stavudine sodium has activity against **HIV-1** and **HIV-2**. Stavudine sodium also inhibits the replication of mitochondrial DNA (mtDNA).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Stavudine-d4

Cat. No.: HY-B0116S

Stavudine-d4 is the deuterium labeled Stavudine. Stavudine (d4T) is an orally active **nucleoside reverse transcriptase** inhibitor **(NRTI)**. Stavudine has activity against **HIV-1** and **HIV-2**. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfadoxine

(Sulphadoxine)

Cat. No.: HY-B0439

Sulfadoxine(Sulphadoxine) is a long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract and malarial infections. Sulfadoxine inhibits **HIV** replication in peripheral blood mononuclear cells.



Purity: 99.44%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Sulfadoxine D3

(Sulphadoxine D3)

Cat. No.: HY-B0439S1

Sulfadoxine D3 is a deuterium labeled Sulfadoxine. Sulfadoxine is a long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract and malarial infections. Sulfadoxine inhibits **HIV replication** in peripheral blood mononuclear cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfadoxine-d4

(Sulphadoxine-d4)

Cat. No.: HY-B0439S

Sulfadoxine-d4 (Sulphadoxine-d4) is the deuterium labeled Sulfadoxine. Sulfadoxine(Sulphadoxine) is a long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract and malarial infections.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sulfametrole

Cat. No.: HY-133937

Sulfametrole is an orally active and potent antibacterial. Sulfametrole can be used for infections research, such as HIV, severe pneumonia and UTIs (urinary tract infections).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

T-peptide

Cat. No.: HY-P2251

T-peptide, a Tuftsin analog, can be used for the research of **human immunodeficiency virus (HIV)** infection. T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. T-peptide also can inhibit the growth of residual tumor cells after surgical resection.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAK-220

Cat. No.: HY-19974

TAK-220 is a selective and orally bioavailable **CCR5** antagonist, with **IC_{50}**s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7; TAK-220 also selectively inhibits **HIV-1**,...



Purity: 99.95%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TAK-779

(Takeda 779)

Cat. No.: HY-13406

TAK-779 is a potent and selective nonpeptide antagonist of **CCR5** and **CXCR3**, with a **K_i** of 1.1 nM for CCR5, and effectively and selectively inhibits **R5 HIV-1**, with **EC_{50}** and **EC_{90}** of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

TAT

Cat. No.: HY-P0281

TAT (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1) and is a cell-penetrating peptide. TAT can increase the yields and the solubility of heterologous proteins.

YGRKKRRQRRR

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

TAT TFA

Cat. No.: HY-P0281A

TAT TFA (YGRKKRRQRRR) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus (HIV-1) and is a cell-penetrating peptide. TAT can increase the yields and the solubility of heterologous proteins.

Purity: 99.07%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tat-beclin 1

Cat. No.: HY-P2260

Tat-beclin 1, a peptide derived from a region of the autophagy protein (beclin 1), is a potent inducer of **autophagy** and interacts with negative regulator of autophagy, GAPR-1 (GLIPR2).

Purity: 99.68%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tat-beclin 1 TFA

Cat. No.: HY-P2260A

Tat-beclin 1 TFA, a peptide derived from a region of the autophagy protein (beclin 1), is a potent inducer of **autophagy** and interacts with negative regulator of autophagy, GAPR-1 (GLIPR2).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TC14012

Cat. No.: HY-P1102

TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic **CXCR4** antagonist with an IC_{50} of 19.3 nM. TC14012 is a potent **CXCR7** agonist with an EC_{50} of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has **anti-HIV** activity and anti-cancer activity.

Purity: 99.43%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

TC14012 TFA

Cat. No.: HY-P1102A

TC14012 TFA, a serum-stable derivative of T140, is a selective and peptidomimetic **CXCR4** antagonist with an IC_{50} of 19.3 nM. TC14012 TFA is a potent **CXCR7** agonist with an EC_{50} of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 TFA has **anti-HIV** activity and anti-cancer activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Temsavir

(BMS-626529)

Cat. No.: HY-15440

Temsavir (BMS-626529) is a novel attachment inhibitor that targets **HIV-1** gp120 and prevents its binding to $CD4^+$ T cells.



Purity: 99.46%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir

(GS 1278; PMPA)

Cat. No.: HY-13910

Tenofovir (GS 1278) is a **nucleotide reverse transcriptase** inhibitor to treat **HIV** and chronic Hepatitis B (**HBV**).



Purity: 99.81%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir alafenamide

(GS-7340)

Cat. No.: HY-15232

Tenofovir alafenamide (GS-7340) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.



Purity: 99.92%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir alafenamide fumarate

(GS-7340 (fumarate))

Cat. No.: HY-15232A

Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir alafenamide hemifumarate

(GS-7340 hemifumarate)

Cat. No.: HY-15232B

Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir alafenamide-d7

(GS-7340-d7) Cat. No.: HY-15232S

Tenofovir alafenamide-d7 (GS-7340-d7) is the deuterium labeled Tenofovir alafenamide. Tenofovir alafenamide (GS-7340) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tenofovir Disoproxil

(Bis(POC)-PMPA; GS 4331) Cat. No.: HY-13782A

Tenofovir Disoproxil (Bis(POC)-PMPA) is a **nucleotide reverse transcriptase inhibitor** to treat HIV and chronic Hepatitis B.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tenofovir Disoproxil fumarate

(Tenofovir DF; Bis(POC)-PMPA fumarate; GS 4331 fumarate) Cat. No.: HY-13782

Tenofovir Disoproxil fumarate is a **nucleotide reverse transcriptase** inhibitor used to treat **HIV** and chronic **Hepatitis B**.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tenofovir exalidex

(CMX-157) Cat. No.: HY-109014

Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant **HIV** strains, including multidrug nucleoside/nucleotide analog-resistant viruses.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tenofovir hydrate

(GS 1278 hydrate; PMPA hydrate) Cat. No.: HY-13910A

Tenofovir hydrate is a **nucleotide reverse transcriptase inhibitor** to treat HIV and chronic Hepatitis B.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tenofovir maleate

(GS 1278 maleate; PMPA maleate) Cat. No.: HY-13910B

Tenofovir Disoproxil Fumarate is a **nucleotide reverse transcriptase inhibitor** to treat HIV and chronic Hepatitis B.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Tenofovir-C3-O-C12-trimethylsilylacetylene ammonium

Cat. No.: HY-139722

Tenofovir-C3-O-C12-trimethylsilylacetylene (ammonium) exhibits substantially longer t1/2 values than tenofovir in human liver microsomes, potent **anti-HIV** activity in vitro, and enhances pharmacokinetic properties in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tenofovir-C3-O-C15-CF3 ammonium

Cat. No.: HY-139721

Tenofovir-C3-O-C15-CF3 (ammonium) exhibits substantially longer t1/2 values than tenofovir in human liver microsomes, potent **anti-HIV** activity in vitro, and enhances pharmacokinetic properties in vivo.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Theaflavin 3,3'-digallate

(TF-3; ZP10) Cat. No.: HY-N1992

Theaflavin 3,3'-digallate (TF-3) is a potent **Zika virus (ZIKV) protease** inhibitor with an IC_{50} of 2.3 μM. Theaflavin 3,3'-digallat directly binds to ZIKVpro (K_d=8.86 μM) and inhibits ZIKV replication.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Thiamine disulfide

Cat. No.: HY-B2224

Thiamine disulfide, a vitamin B1 derivative, is an oxidized dimer of Thiamine. Thiamine disulfide is a potent **HIV-1** inhibitor. Thiamine disulfide significantly depresses HIV-1 transactivator (Tat) activity.



Purity: 95.44%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

Tigloylgomisin P

Cat. No.: HY-N7586

Tigloylgomisin P, a lignin, has anti-**HIV** activity with an EC_{50} of 37 μM. Tigloylgomisin P has anticancer effect.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 5 mg

Tipranavir

(PNU-140690)

Cat. No.: HY-15148

Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of **HIV-1 protease**, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC_{50}s of 66-410 nM. Tipranavir inhibits SARS-CoV-2 $3CL^{pro}$ activity.



Purity: 98.08%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Tipranavir-d4

Cat. No.: HY-15148S

Tipranavir-d4 (PNU-140690-d4) is the deuterium labeled Tipranavir. Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of **HIV-1 protease**, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC_{50}s of 66-410 nM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Tizoxanide

(TIZ)

Cat. No.: HY-12687

Tizoxanide is the active metabolite of Nitazoxanide, which is a thiazolide anti-infective compound against anaerobic bacteria, protozoa, and a range of viruses. Tizoxanide has **anti-HIV-1** activities.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Tizoxanide D4

Cat. No.: HY-12687S

Tizoxanide D4 (TIZ D4) is the deuterium labeled Tizoxanide. Tizoxanide is the active metabolite of Nitazoxanide, which is a thiazolide anti-infective compound against anaerobic bacteria, protozoa, and a range of viruses. Tizoxanide has **anti-HIV-1** activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triciribine

(API-2; NSC 154020; TCN)

Cat. No.: HY-15457

Triciribine is a **DNA synthesis** inhibitor, also inhibits **Akt** and **HIV-1/2** with IC_{50} of 130 nM, and 0.02-0.46 μM, respectively.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Trilobatin

Cat. No.: HY-N4100

Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd, Trilobatin is an **HIV-1** entry inhibitor targeting the HIV-1 Gp41 envelope. Neuroprotective effects.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL,

Tripterifordin

Cat. No.: HY-N6080

Tripterifordin possesses significant anti-**HIV** replication activities in H9 lymphocyte cells with an EC_{50} value of 3100 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Triptonine B

Cat. No.: HY-N3511

Triptonine B, a sesquiterpene pyridine alkaloid, inhibits **HIV** replication in H9 lymphocytes with an EC_{50} value of <0.10 μg/mL.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trovirdine

(LY300046)

Cat. No.: HY-15349

Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Valproic acid

(VPA; 2-Propylpentanoic Acid) Cat. No.: HY-10585

Valproic acid (VPA; 2-Propylpentanoic Acid) is an **HDAC** inhibitor, with IC_{50} in the range of 0.5 and 2 mM, also inhibits **HDAC1** (IC_{50}, 400 μM), and induces proteasomal degradation of **HDAC2**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g, 25 g

Valproic acid sodium

(Sodium Valproate sodium) Cat. No.: HY-10585A

Valproic acid sodium salt (Sodium Valproate) is an **HDAC** inhibitor, with IC_{50} in the range of 0.5 and 2 mM, also inhibits **HDAC1** (IC_{50}, 400 μM), and induces proteasomal degradation of **HDAC2**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 500 mg, 1 g, 5 g, 25 g

Valproic acid-d14 sodium

(Sodium Valproate-d14 sodium) Cat. No.: HY-10585AS1

Valproic acid-d14 (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Valproic acid-d15

(VPA-d15; 2-Propylpentanoic Acid-d15) Cat. No.: HY-10585S2

Valproic acid-d15 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an **HDAC** inhibitor, with IC_{50} in the range of 0.5 and 2 mM, also inhibits **HDAC1** (IC_{50}, 400 μM), and induces proteasomal degradation of **HDAC2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Valproic acid-d4

(VPA-d4; 2-Propylpentanoic Acid-d4) Cat. No.: HY-10585S

Valproic acid-d4 (VPA-d4) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an **HDAC** inhibitor, with IC_{50} in the range of 0.5 and 2 mM, also inhibits **HDAC1** (IC_{50}, 400 μM), and induces proteasomal degradation of **HDAC2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Valproic acid-d4 sodium

(VPA-d4 sodium; 2-Propylpentanoic Acid-d4 sodium) Cat. No.: HY-10585S3

Valproic acid-d4 (VPA-d4) sodium is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an **HDAC** inhibitor, with IC_{50} in the range of 0.5 and 2 mM, also inhibits **HDAC1** (IC_{50}, 400 μM), and induces proteasomal degradation of **HDAC2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Valproic acid-d4-1

(VPA-d4-1; 2-Propylpentanoic Acid-d4-1) Cat. No.: HY-10585S4

Valproic acid-d4-1 (VPA-d4-1) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an **HDAC** inhibitor, with IC_{50} in the range of 0.5 and 2 mM, also inhibits **HDAC1** (IC_{50}, 400 μM), and induces proteasomal degradation of **HDAC2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Valproic acid-d6

(VPA-d6; 2-Propylpentanoic Acid-d6) Cat. No.: HY-10585S1

Valproic acid-d6 (VPA-d6) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an **HDAC** inhibitor, with IC_{50} in the range of 0.5 and 2 mM, also inhibits **HDAC1** (IC_{50}, 400 μM), and induces proteasomal degradation of **HDAC2**.



Purity: 98.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Valproic acid-d7 sodium

(Sodium Valproate-d7 sodium) Cat. No.: HY-10585AS

Valproic acid-d7 (Sodium Valproate-d7) sodium is the deuterium labeled Valproic acid (sodium salt).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Vesatolimod

(GS-9620) Cat. No.: HY-15601

Vesatolimod (GS-9620) is a potent, selective and orally active agonist of **Toll-Like Receptor (TLR7)** with an EC_{50} of 291 nM.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vesnarinone

(OPC-8212) Cat. No.: HY-15297

Vesnarinone is a quinolinone derivative, and its pharmacodynamic effects include inhibition of phosphodiesterase Ⅲ (PDE3) activity, increases in calcium flux and decreases in potassium flux.



Purity: 98.07%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Vicriviroc maleate

(SCH-417690 maleate; SCH-D maleate) Cat. No.: HY-17377

Vicriviroc maleate (SCH-417690 maleate; SCH-D maleate) is a potent, selective, oral bioavailable and CNS penetrated antagonist of **CCR5**, with a K_i of 2.5 nM, and also inhibits HIV-1 in PBMC cells, with IC_{90}s of 3.3 nM (JrFL), 2.8 nM (ADA-M), 1.8 nM (301657), 4.9 nM (JV1083) and 10 nM (RU570).



Purity: 99.91%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Wilfortrine

Cat. No.: HY-N3506

Wilfortrine is a bioactive sesquiterpene alkaloid. Wilfortrine exhibits immunosuppresive effects. Wilfortrine also can inhibit leukaemia cell growth in mice and shows anti-HIV activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

WRNA10

Cat. No.: HY-146382

WRNA10 is a potent **HIV-1** TAR RNA binder with an IC_{50} of 10 μM and an CC_{50} of 40 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

YYA-021

Cat. No.: HY-100039

YYA-021 is a small-molecule CD4 mimic that inhibits HIV entry, with high anti-HIV activity and low cytotoxicity. IC50 value: 8.4 μM Target: HIV IC50 (=8.4 μM) value of YYA-021 is determined by a single round assay using cYTA48P virus and TZM-bl cells.



Purity: 98.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zalcitabine

(2',3'-Dideoxycytidine; ddC; Dideoxycytidine) Cat. No.: HY-17392

Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of **HIV** infection.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Zidovudine

(Azidothymidine; AZT; ZDV) Cat. No.: HY-17413

Zidovudine is a nucleoside reverse transcriptase inhibitor (**NRTI**), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Zidovudine-13C,d3

(Azidothymidine-13C,d3; AZT-13C,d3; ZDV-13C,d3) Cat. No.: HY-17413S1

Zidovudine-13C,d3 is the 13C- and deuterium labeled. Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zidovudine-d3

(Azidothymidine-d3; AZT-d3; ZDV-d3) Cat. No.: HY-17413S

Zidovudine-d3 (Azidothymidine-d3) is the deuterium labeled Zidovudine. Zidovudine is a nucleoside reverse transcriptase inhibitor (**NRTI**), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZINC04177596

Cat. No.: HY-119210

ZINC04177596 is a potent HIV-negative factor **(HIV-Nef) protein** inhibitor. Nef is an accessory gene product of HIV and has an imperative role in viral replication and AIDS pathogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Zingibroside R1

Cat. No.: HY-N6924

Zingibroside R1 is dammaranae-type triterpenoid saponin, isolated from rhizomes, taproots, and lateral roots of Panax japonicas C. A. Meyer, shows excellent anti-tumor effects as well as anti-angiogenic activity. Zingibroside R1 possesses some anti-**HIV-1** activity.



Purity: 99.75%
Clinical Data:
Size: 5 mg, 10 mg

ZL0580

Cat. No.: HY-126428

ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of **HIV** via selectively binding to BD1 domain of **BRD4**.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

α-Lipoic Acid

(Thioctic acid; (±)-α-Lipoic acid; DL-α-Lipoic acid)

Cat. No.: HY-N0492

α-Lipoic Acid is an antioxidant, which is an essential cofactor of **mitochondrial** enzyme complexes. α-Lipoic Acid inhibits **NF-κB**-dependent **HIV-1** LTR activation. α-Lipoic Acid induces endoplasmic reticulum (ER) stress-mediated **apoptosis** in hepatoma cells.



Purity: 98.03%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg

α-Lipoic Acid-d5 (Thioctic acid-d5; (±)-α-Lipoic acid-d5; DL-α-Lipoic acid-d5)

Cat. No.: HY-N0492S

α-Lipoic Acid-d5 (Thioctic acid-d5) is the deuterium labeled α-Lipoic Acid. α-Lipoic Acid is an antioxidant, which is an essential cofactor of **mitochondrial** enzyme complexes. α-Lipoic Acid inhibits **NF-κB**-dependent **HIV-1** LTR activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

β-Rubromycin

Cat. No.: HY-122482

β-Rubromycin is a potent and selective inhibitor of human immunodeficiency virus-1 (HIV-1) RNA-directed DNA polymeras (**reverse transcriptase**). β-Rubromycin is a class of quinone antibacterials.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg